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• Background:  The  incidence  and  mortality  rates  of  cervical  cancer  in  Haiti  are  
among  the  highest  in  the  world,  yet  the  screening  coverage  rate  is  among  the  
lowest.    Efforts  to  ameliorate  this  problem  using  cytology-­‐‑based  programs  have  
fallen  short  due  to  geographic,  socioeconomic,  cultural,  and  infrastructural  
barriers  to  access.    A  prevention  strategy  based  on  vaginal,  self-­‐‑screening  for  
high-­‐‑risk  (HR)  HPV  in  communities  may  increase  coverage  by  avoiding  or  
diminishing  these  impediments.    This  study  examined  the  diagnostic  
performance  of  self-­‐‑screening  when  compared  to  clinician  screening  in  two  
clinics  in  Port-­‐‑au-­‐‑Prince.  
• Methods:  1836  women  participated  in  a  cross-­‐‑sectional  study  in  which  each  
underwent  vaginal  and  cervical  screening  for  HR  HPV,  and  HIV  rapid  testing.    
HR  HPV  positive  women  returned  for  follow-­‐‑up  testing  with  colposcopy  and  
biopsy.    Data  analysis  explored  the  concomitant  tests'ʹ  comparative  performance  
using  percent  agreements  with  Kappa  statistics,  test  positivity,  and  the  ability  to  
detect  various  levels  of  biopsy-­‐‑confirmed  cervical  intraepithelial  neoplasia.    Age-­‐‑
related  prevalence  rates  were  also  determined.    Statistical  associations  were  
measured  using  Chi-­‐‑Square,  Fisher’s  Exact,  and  McNemar’s  Tests.  
    
v  
• Results:  Overall  concomitant  test  agreement  was  strong  (91.39%,  K=0.73),  but  
varied  with  statistical  significance  by  age  in  the  youngest  and  oldest  quartiles.    
Women  between  42  and  48  years  old  demonstrated  the  highest  concordance  
(93.45%,  K=0.70).    Vaginal  test  positivity  was  uniformly  higher  than  cervical  test  
positivity  among  participants  of  all  ages.    Vaginal  samples  identified  84.46%  of  
HR  HPV  cases  that  cervical  samples  identified,  and  more  than  90%  of  all  high-­‐‑
grade  disease.    However,  clinician  screening  accurately  detected  several  more  
clinically  relevant  cases  of  disease  (≥  CIN  I)  (56)  than  self-­‐‑screening  (53).  
• Conclusion:  Strong  test  agreement  indicated  that  vaginal  screening  produced  
comparable  results  to  clinician  screening,  and  age-­‐‑related  statistics  may  be  able  
to  inform  test  algorithms  in  the  future.    With  plans  to  establish  pathology  labs  in  
Leogane  and  Port-­‐‑au-­‐‑Prince  that  employ  local  talent  and  utilize  the  relatively  
affordable  CareHPV  Assay  (QIAGEN),  self-­‐‑screening  may  be  a  diagnostically  
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1. Introduction  
Cervical  cancer,  the  seventh  most  common  cancer  in  the  world1,  is  a  disease  of  
disparity.    Both  incidence  and  mortality  are  disproportionately  greater  among  women  
living  in  low-­‐‑  and  middle-­‐‑income  countries  (LMICs)  than  those  in  high-­‐‑income  
countries  (HICs).      Of  the  roughly  525,000  cases  of  cervical  cancer  that  occur  annually,  
86%  are  in  LMICs.    Of  the  roughly  275,000  women  who  die  from  the  disease  each  year,  
88%  are  in  LMICs  1.    Unfortunately,  Haiti  is  a  developing  country  emblematic  of  these  
statistics.      
Haiti  has  the  highest  reported  cervical  cancer  incidence  rate  (age-­‐‑adjusted:  93.9/  
100,000)  and  mortality  rate  (age-­‐‑adjusted:  53.5/  100,000)  in  the  Americas2.    By  the  year  
2025,  the  International  Agency  for  Research  on  Cancer  (IARC)  estimates  that  as  the  
population  grows  and  ages,  the  annual  number  of  cervical  cancer  deaths  in  Haiti  will  be  
55%  higher  than  in  2008  1.    This  is  a  devastating  projection,  given  that  cervical  cancer  
already  accounts  for  49%  of  all  cancer  deaths  in  the  entire  population3,  and  63%  of  all  
cancer  deaths  in  women4.    
It  is  possible  to  reverse  these  numbers,  however,  with  the  implementation  of  a  
national  cervical  cancer  prevention  program  in  Haiti.    Decades  of  research  from  the  
United  States  and  Western  Europe  have  demonstrated  that  cervical  cancer  incidence  and  
prevalence  can  be  halved  through  the  inauguration  of  regular  screening  practices  that  
reach  a  high  percentage  of  the  population.    While  cytology  is  the  current  method  of  
choice  in  high-­‐‑income  countries,  it  has  routinely  failed  to  have  a  positive  impact  in  low  
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and  middle-­‐‑income  countries  where  infrastructure  is  weak,  skilled  pathologists  are  few,  
money  is  scarce,  misconceptions  are  rampant,  and  transportation  is  difficult.    In  Haiti,  an  
inaugural,  cytology-­‐‑based  screening  strategy  struggled  with  many  of  these  issues,  as  
well  as  the  high  prevalence  of  reproductive  tract  inflammation.    Family  Health  
Ministiries  (FHM),  the  non-­‐‑governmental  organization  (NGO)  that  piloted  the  program,  
discovered  obscuring  inflammation  on  85%  of  cervical  cytology  slides  from  women  who  
had  been  pretreated  with  antibiotics  for  clinically-­‐‑evident  vaginal  infections5.      
Visual  inspection  with  acetic  acid  (VIA)  has  also  been  employed  in  many  
developing  countries  in  the  hopes  of  countering  cost  and  reducing  the  need  for  skilled  
labor.    However,  research  suggests  that  VIA’s  quality  assurance  and  sensitivity  results  in  
significant  numbers  of  missed  cases  of  disease.    Most  notably,  in  a  large,  randomized  
cluster,  controlled  trial  in  India6  of  more  than  130,000  women,  clusters  of  villages  that  
underwent  either  cytology  or  VIA  experienced  no  significant  reductions  in  the  number  
of  advanced  cervical  cancer  cases  or  associated  mortalities  relative  to  the  control  group,  
which  received  the  standard  of  care.    In  contrast,  those  women  who  received  HPV  
testing  showed  significantly  lower  incidence  and  mortality  rates.    Given  these  
compelling  findings,  we  decided  to  explore  patient-­‐‑collected  HPV  testing  as  a  potential  
primary  screen  for  cervical  cancer  prevention  in  Haiti.      
Self-­‐‑performed  HPV  screening  has  the  potential  to  increase  Haiti’s  screening  
coverage  (last  measured  in  the  1980s  as  approximately  5%7,8)  by  overcoming  barriers  to  
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access.    Many  studies  from  around  the  world,  including  from  “Little  Haiti,”  a  bastion  of  
Haitian  immigrants  in  Miami,  have  demonstrated  overwhelming  acceptance  of,  and  
often  preference  for,  vaginal  self-­‐‑sampling  for  HPV.    Research  has  also  shown  that  this  
method  of  screening  is  diagnostically  sound  when  compared  to  the  highly  sensitive  and  
specific  method  of  clinician-­‐‑performed  HPV  screening.    However,  some  variation  in  the  
strength  of  agreement  has  been  observed,  and  some  postulate  that  the  testing  
instrument,  size  or  location  of  the  sample,  detection  target  (high-­‐‑grade  or  low-­‐‑grade  
disease),  and  population  characteristics  can  offer  insight  into  the  discrepancies9,10.    Most  
notably,  it  has  been  established  that  HPV  DNA  test  performance  is  affected  by  the  
prevalence  of  HPV,  which  varies  by  age11–13.    Despite  this  awareness,  current  
manufacturers  of  the  Hybrid  Capture  II  Technology  (hc2)  (QIAGEN  Corporation,  
Gaithersburg,  Maryland)  –  the  most  widely  used  HPV  DNA  test  in  clinical  settings  –  
recommend  an  interpretive  algorithm  that  is  the  same  for  all  women14.    
To  understand  the  suitability  of  HPV  self-­‐‑screening  to  the  Haitian  context,  it  is  
important  to  determine  not  only  the  overall  concordance  of  the  concomitant  tests,  but  
also  to  probe  the  tests’  performance  in  women  with  different  ages,  levels  of  cervical  
intraepithelial  neoplasia,  and  in  the  future,  HPV  viral  loads.    Understanding  these  
relationships  can  help  optimize  diagnostic  performance  and  influence  implementation  
strategies.    In  a  country  starving  for  health  statistics,  exploring  these  topics  could  
provide  valuable  insight  for  clinicians  and  politicians  alike.  
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2. Study Objectives and Hypotheses 
With  the  gravity  of  cervical  cancer  and  the  lack  of  available  screening  in  mind,  
this  study  pursued  two  objectives:  1)  to  determine  if  self-­‐‑screening  for  high-­‐‑risk  (HR)  
HPV  is  a  suitable  cervical  cancer  prevention  method  in  Haiti  based  on  its  diagnostic  
performance;  and  2)  to  lay  a  foundation  of  age-­‐‑related  data  that  can  be  used  to  
understand  results  and  optimize  test  sensitivity  and  specificity  in  the  future.    Several  
hypotheses  accompanied  each  of  these  objectives.  
In  assessing  the  primary  objective:      
• Self-­‐‑collected,  vaginal  samples’  results  will  agree  with  clinician-­‐‑collected,  
cervical  samples’  results  in  at  least  85%  of  patients.    
• Self-­‐‑screening  will  identify  at  least  85%  of  all  cases  of  HR  HPV  that  would  
have  been  identified  by  clinician-­‐‑performed  screening  alone.  
• Self-­‐‑screening  will  identify  at  least  85%  of  histologically-­‐‑confirmed  cases  
of  ≥  CIN  I  and  ≥  CIN  II.    
In  assessing  the  secondary  objective:  
• HR  HPV  prevalence,  measured  by  both  vaginal  and  cervical  screening,  
will  vary  with  statistical  significance  by  age  quartile.  
• Self-­‐‑screening  and  clinician-­‐‑screening  will  return  statistically  similar  
results  (p  >  0.05)  in  each  age  quartile.  
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3. Thesis Structure 
To  best  accomplish  these  objectives,  this  thesis  is  divided  into  several  sections  
that  intend  to  fully  explain  the  research’s  context,  execution,  and  future  application.    
First,  a  review  of  the  relevant  literature  describes  the  determinants  of  cervical  cancer,  the  
barriers  developing  countries  face  in  screening  for  the  disease,  the  reasons  for  choosing  
self-­‐‑screening  over  alternatives,  and  HPV  tests’  diagnostic  performance  in  self-­‐‑collected  
samples.    Next,  the  study’s  setting,  clinical  procedures,  and  methods  of  analysis  are  
described  in  detail,  followed  by  some  of  the  methods’  limitations.    The  results  of  the  
quantitative  analysis  then  appear  in  both  written  and  tabular  form.    In  the  order  in  
which  the  research  objectives  and  hypotheses  were  first  presented,  the  results  are  
discussed  in  the  context  of  previous  literature.    A  conclusion  section  then  summarizes  








4. Background  
 
4.1 Determinants of Disease 
The  two  major  determinants  of  cervical  cancer  incidence  are  persistent,  
carcinogenic  (or  “high-­‐‑risk”)  human  papillomavirus  (HPV)  infection,  and  lack  of  access  
to  screening  15.    Notable  risk  factors  for  cervical  cancer  include:  sexual  activity  at  an  early  
age,  multiple  sexual  partners,  exposure  to  other  sexually  transmitted  diseases,  cigarette  
smoking,  oral  contraceptive  use,  human  immunodeficiency  virus  (HIV),  and  
immunosuppressive  drug  therapy16.    While  cervical  cancer  is  associated  with  these  
factors,  it  is  important  to  note  that  HPV,  the  virus  that  leads  to  nearly  100%  of  cervical  
cancer  cases,  is  fairly  ubiquitous  among  the  human  population.    For  example,  by  the  age  
of  50,  80%  of  sexually  active  women  in  America  will  have  acquired  an  HPV  infection  at  
some  time  in  their  lives17.    
4.1.1 High-Risk Human Papillomavirus Infection and Persistence 
Of  the  roughly  100  phylogenetic  types  of  HPV,  over  40  infect  the  basal  or  
mucosal  epithelial  cells  of  the  male  and  female  genitalia  and  oropharyngeal  tracts.    
These  are  classified  as  “low-­‐‑risk”  (LR)  or  “high-­‐‑risk”  (HR)  based  on  their  oncogenic  
potentials.    LR  HPV  can  cause  warts,  while  HR  HPV  can  cause  cancer  over  time—
typically  years  or  decades  after  initial  infection18,19.    Anogenital  transmission  mainly  
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occurs  through  skin-­‐‑to-­‐‑skin  or  mucosa-­‐‑to-­‐‑mucosa  contact  20,21,  but  the  precise  mechanism  
of  pathogenesis  is  unknown.      
According  to  the  cervicovaginal  challenge  model,  viral  infection  occurs  via  
uptake  and  internalization.    First,  the  small  HPV  virus  bypasses  the  squamous  epithelial  
layer  of  the  transformation  zone  (a  transitional  area  of  the  cervical  canal  where  
glandular  epithelia  are  replaced  by  squamous  epithelia)  via  a  microabrasion  that  
exposes  the  basement  membrane.    Second,  after  undergoing  conformational  changes  
achieved  through  antigen  binding  and  cleavage,  the  virion  is  recognized  by  cellular  
receptors  on  the  basal  target  cells,  allowing  for  internalization  22.    By  activating  cellular  
DNA  replication  factors,  widespread  infection  of  the  epithelia  can  occur  within  two  to  
three  days  20,23.        
While  the  vast  majority  of  infections—particularly  those  in  immuno-­‐‑competent  
women  younger  than  25—are  cleared  or  suppressed  within  two  years  by  cell-­‐‑mediated  
immunity,  some  endure  and  even  advance  towards  cervical  cancer  24.    Dysplastic  
cellular  changes  in  the  transformation  zone  create  lesions  known  as  “Cervical  Intra-­‐‑
epithelial  Neoplasia”  (CIN)  or  “Squamous  Intraepithelial  Lesion”  (SIL).    Typically,  43%  
of  low-­‐‑grade  SIL  (“LSIL,”  or  CIN  I  and  II)  and  92%  of  high-­‐‑grade  SIL  (“HSIL,”  or  CIN  
III)  either  persist  or  progress  25.    Of  the  aggressively  persistent  HPV  infections  that  
develop  into  cancer,  80  to  90%  are  called  “squamous  cell  carcinomas,”  because  they  
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develop  within  the  squamous  cells  of  the  ectocervix.    The  remaining  10  to  20%  of  cases  
are  adenocarcinomas,  which  occur  in  the  columnar  or  glandular  cells  of  the  endocervix26.      
Research  has  exposed  13  HPV  types  as  the  culprits  of  these  persistent  
precancerous  infections,  HSIL,  and  cervical  cancers  —16,  18,  31,  33,  35,  39,  45,  51,  52,  56,  
58,  59,  68,  and  82.    Although  geographic  differences  do  occur,  the  most  prevalent  types  
reported  worldwide  are  16  and  18,  which  account,  respectively,  for  20-­‐‑30%  and  50-­‐‑70%  
of  invasive  cervical  cancer  cases  in  symptomatic  and  asymptomatic  women  
worldwide18,23.      Data  collected  by  Family  Health  Ministries’  clinics  in  Leogane  and  Port-­‐‑
au-­‐‑Prince  indicate  that  the  most  prevalent  HR  HPV  types  found  in  both  single  and  
multiple  infections  among  269  Haitian  women  were:    52  (11%),  16  (11%),  18  (10%),  35  
(8%),  and  31  (7%).    HPV16  and  HPV35  were  the  most  common  genotypes  detected  in  ≥  
CIN  II,  and  both  were  found  more  often  in  women  with  high-­‐‑grade  disease  than  those  
without.    Consistent  with  other  global  findings,  HPV16  and/or  HPV18  were  detected  in  
21.0%  of  CIN  II  (n  =  42),  46.2%  of  CIN  III  (n  =  52),  and  80%  of  cancers  (n  =  5).    These  
statistics,  while  preliminary,  suggest  that  the  currently  available  bivalent  and  
quadrivalent  HPV  vaccines  currently  on  the  market—which  target  types  16  and  18  and  
6,  11,  16  and  18,  respectively—  may  be  less  effective  at  reducing  cervical  cancer  
incidence  and  mortality  in  Haiti  than  in  other  parts  of  the  globe27.    This  possibility  
underscores  the  importance  of  screening  in  preventing  cervical  cancer.  
    
9  
4.1.2 Lack of Cervical Cancer Screening 
Despite  Haiti’s  high  incidence  rate,  the  country  lacks  a  national  cervical  cancer  
prevention  program,  and  one  estimate  suggests  that  only  5%  of  at-­‐‑risk  women  are  
screened7,8.    This  coverage  rate  is  similar  to  those  reported  in  Malawi,  Ethiopia,  and  
Bangladesh.    In  stark  contrast,  the  percent  coverage  rates  in  many  developed  countries  
are  in  the  mid-­‐‑90s28.    Over  the  last  few  decades  in  certain  HICs,  effective  screening  
practices  have  led  to  dramatic  reductions  of  between  50  and  80%  in  cervical  cancer  
incidence  and  mortality1,29,30.    Specifically,  incidence  in  Finland  decreased  by  roughly  
80%  between  1962  and  1993,  while  mortality  dropped  by  75%  in  the  United  States  
between  the  1960s  and  new  millennium30,31.    The  impact  of  screening  on  incidence  and  
mortality  is  evident;  however,  program  designs  and  implementation  strategies  that  have  
proven  effective  in  developed  countries  are  not  necessarily  transposable  to  developing  
countries  like  Haiti,  where  the  barriers  to  access  are  many  and  varied.  
  
4.2 Barriers to Access in Developing Countries    
Cervical  cancer  screening  is  impeded  in  LMICs  by  structural  and  intrapersonal  
factors  that  are  less  common  in  HICs.    Varughese  and  Richman  (2010)  identify  low  
literacy,  culture  and  religion,  competing  health  needs,  poorly  developed  health  systems,  
limited  information  on  cancer  prevention,  lack  of  infrastructure,  and  geographic  
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isolation  (which  incurs  time  and  transportation  costs)  as  impediments  to  cervical  cancer  
screening  in  developing  countries32.      
Country  data  from  prevention  programs  in  Latin  America  and  the  Caribbean,  
summarized  in  a  2004  report  by  the  Pan-­‐‑American  Health  Organization  (PAHO),  
exemplify  these  barriers.    Specifically,  studies  from  Costa  Rica,  Peru,  Mexico,  and  Bolivia  
indicate  wide  intra-­‐‑country  variations  in  cervical  cancer  incidence  based  on  women’s  
geographic  isolation,  poverty,  and  lack  of  education.    Cytology-­‐‑based  screening  
programs  in  the  region  have  also  reported  resistance  to  participation  because  of  patients’  
attitudes  towards  screening,  diagnosis,  and  treatment.    Many  women  report  that  the  
impersonal  manner  and/or  male  gender  of  clinicians  deter  them  from  having  a  pap  
smear  taken.    Others  are  fearful  of  cervical  cancer  diagnosis  and  treatment,  believing  
that  cervical  cancer  is  a  death  sentence33.    It  is  therefore  evident  that  the  reasons  belying  
poor  coverage  rates  in  parts  of  Latin  America  and  the  Caribbean  are  multifaceted  and  
entangled  in  complicated  development  and  sociocultural  issues.  
The  paucity  of  research  conducted  on  this  subject  in  Haiti  corroborates  the  
findings  from  elsewhere  in  the  region.    In  personal  communication  (May  25,  2012),  Drs.  
David  Walmer  and  Nicole  Tinfo  of  Family  Health  Ministries  (FHM)  cited  transportation  
costs  and  geographic  barriers  as  reasons  for  a  50%  loss  to  follow-­‐‑up  in  a  cytology-­‐‑based  
screening  program  in  Leogane,  Haiti,  which  ran  from  2009  –  2011.    In  her  Master’s  thesis  
(2011),  Marie  Hilaire  also  concluded,  through  univariate  and  multivariate  analyses  of  
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five  cervical  cancer  predictor  variables  from  the  Haitian  Demographic  and  Health  
Survey  of  2005-­‐‑2006,  that  pecuniary  and  geographic  obstacles  were  correlated  with  
cervical  cancer  (and  by  proxy,  with  screening).    Hilaire  found  that  both  crude  and  
adjusted  logistic  regression  models  demonstrated  that  women  with  low  educational  
attainment  and  socioeconomic  status  have  increased  odds  of  developing  cervical  cancer  
compared  to  the  referent  group8.    The  crude  model  also  pegged  rural  residence  as  a  risk  
factor.    It  is  important  to  note,  however,  that  three  dependent  variables  of  questionable  
suitability  were  used  as  proxies  for  the  outcome  of  interest,  high  risk  of  cervical  cancer:  
young  age  (less  than  20  years  old)  of  first  sexual  intercourse,  multiple  lifetime  sex  
partners,  and  inability  to  ask  partner  to  use  a  condom.    The  author  describes  neither  the  
biological  nor  socio-­‐‑cultural  reasons  for  selecting  20  years  as  an  age  of  significance  in  the  
development  of  cervical  cancer.    Furthermore,  the  “condom  variable”  falsely  equates  
women’s  ability  to  ask  for  protection  with  reduced  or  negligible  exposure  to  HR  HPV.    
Asking  does  not  ensure  utilization;  utilization  does  not  ensure  accurate  utilization  for  
the  duration  of  every  sexual  encounter;  and  even  perfect  utilization  does  not  ensure  
protection  from  HPV  transmission.      
While  Hilaire’s  thesis  contains  methodological  shortcomings,  it  represents  the  
only  known  research  of  its  kind  in  Haiti,  and  therefore  is  cautiously  considered  evidence  
of  cervical  cancer’s  connection  to  poverty,  lack  of  education,  and  rural  residency  in  
Haiti.    Until  robust  statistics  are  available,  Haitian  policymakers  and  public  health  
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officials  must  review  the  successes  and  failures  of  other  countries’  battles  against  
cervical  cancer  to  inform  their  own  country’s  cervical  cancer  prevention  program.  
  
4.3 Assessment of Cervical Cancer Screening Methods 
In  general,  the  most  impactful  programs—those  that  effectively  reduce  the  
incidence  and  mortality  of  cervical  cancer  by  detecting  and  treating  precancerous  
lesions—  employ  tests  that  are  relatively  simple,  inexpensive,  sensitive  and  specific,  
painless,  and  socio-­‐‑culturally  acceptable.    They  can  be  applied  to  large  numbers  of  
asymptomatic  people  in  order  to  classify  them  as  likely  or  unlikely  to  have  cervical  
dysplasia,  and  women  with  positive  results  can  then  be  further  investigated  or  treated34.    
Many  different  screening  techniques  have  been  employed  in  LMICs  with  varying  
success.    An  examination  of  these  techniques  supports  the  potential  suitability  of  vaginal  
self-­‐‑screening  to  the  Haitian  context.      
4.3.1 Cytology 
Cytology,  also  known  as  the  Papanicolaou  test  or  pap  smear,  is  likely  the  most  
widely  used  cervical  cancer  screening  technique  in  the  world35.    In  high-­‐‑income  
countries  with  robust  health  infrastructures,  broad  screening  coverage,  and  reliable  
patient  follow-­‐‑up,  conventional  and  liquid-­‐‑based  cytology  has  diminished  cervical  
cancer  incidence  and  mortality  dramatically.    In  the  United  States,  pap  smears  were  
introduced  in  1945  and  are  still  used  as  the  primary  screening  method  for  women  aged  
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21  and  older.    Unfortunately,  cytology-­‐‑based  screening  programs  in  low-­‐‑income  
countries  have  floundered.    In  Latin  America  and  the  Caribbean,  specifically,  
documented  problems  with  cytological  screening  include  the  low  quality  of  smear  
sampling,  collection,  preparation,  and  interpretation33.    These  problems  are  traceable  to  
three  sources:  high  cost,  reliance  upon  skilled  labor,  and  weak  sensitivity  of  detecting  
HSIL  and  cancer32,36.  
Cytology  screening  is  expensive  because  of  the  requisite  equipment,  skilled  
labor,  and  infrastructure.    Tools  are  needed  for  sample  collection  (e.g.  speculum),  
processing  (e.g.  slide  stains),  and  interpretation  (e.g.  microscopes).    Highly-­‐‑trained  
nurses  or  doctors  are  needed  to  perform  pap  smears,  while  cytotechnologists  and  
pathologists  are  needed  to  render  quality-­‐‑assured  diagnoses.    In  addition  to  the  physical  
infrastructure  necessary  to  conduct  clinical  and  diagnostic  functions,  cytology-­‐‑based  
programs  require  organized,  programmatic  infrastructure  that  enables  patient  tracking  
and  adherence  to  follow-­‐‑up36.    Maintaining  patient  registries  and  contacting  women  for  
test  results,  colposcopies,  and  treatment  are  salient  to  this  method’s  success,  because  
they  ensure  repetitive  screening  and  relatively  short  testing  intervals.      
Frequent  testing  and  follow-­‐‑up  visits  are  needed  because  when  used  on  its  own,  
cytology  has  a  relatively  low  sensitivity.    Meta-­‐‑analyses  and  recent,  large  studies  have  
demonstrated  that  the  sensitivity  of  a  single  pap  smear  is  between  49%  and  57%  for  
HSIL  and  cancer36.    In  countries  where  women  are  screened  only  once  or  twice  during  
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their  lifetimes,  if  at  all,  this  sensitivity  range  is  not  strong  enough  to  mitigate  the  national  
burden  of  disease.    Assuming  100%  of  women  are  screened,  but  only  once  in  their  
lifetimes,  using  pap  smears  alone  would  prevent  over  40%  of  women  with  HSIL  and  
cancer  from  receiving  accurate  diagnoses  and  treatments.    It  has  been  suggested  that  
combining  cytology  with  a  second  test  would  increase  sensitivity  while  reducing  testing  
intervals;  however,  the  cost-­‐‑effectiveness  of  this  strategy  remains  to  be  established34.    
Using  pap  tests  to  correctly  identify  women  with  HSIL  is  especially  challenging  
in  the  presence  of  cervical  tissue  inflammation,  which  can  obscure  malignant  cells  and  
lead  to  high  rates  of  false  negative  diagnoses37.    While  inflammation  is  often  caused  by  
benign  conditions  like  vaginal  infections,  it  is  associated  with  a  number  of  sexually-­‐‑
transmitted  infections  and  malignant  neoplasia37–41.      In  fact,  data  from  Hammes  and  
colleagues  (2007)  in  Brazil  demonstrated  a  direct,  linear  relationship  between  
inflammation  and  disease  progression;  inflammation  was  present  in  25%,  46.1%,  58.4%,  
and  89.3%  of  benign  tissue,  LGSIL,  HGSIL  and  squamous  cell  carcinoma,  respectively42.    
The  connection  between  inflammation  and  false  negative  results  are  especially  
important  in  Haiti  where  the  prevalence  of  the  former  is  high,  and  the  consequence  of  
the  latter  is  dire.    Between  2009  and  2011,  gynecologists  performing  pap  smears  at  two  
FHM  clinics  in  Haiti  observed  obscuring  inflammation  in  as  many  as  85%  of  cervical  
specimens5.    While  uninvestigated  at  this  point,  researchers  from  the  University  of  
Miami  have  hypothesized  that  the  inflammation  is  related  to  a  high  frequency  of  vaginal  
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cleansing  (two  to  three  times  daily)  using  both  natural  and  commercial  products43.    This  
practice,  performed  in  many  parts  of  Africa  as  well,  is  intended  to  dry  and  tighten  the  
vagina  for  men’s  sexual  pleasure44,45.    While  liquid-­‐‑based  cytology  is  believed  to  have  
increased  sensitivity  over  conventional  cytology  in  cases  of  inflammation46,  its  benefits  
are  potentially  nullified  by  its  relatively  higher  cost36.    Another  Duke  Masters  in  Global  
Health  student,  Genevieve  Wolpert,  is  currently  investigating  this  possibility  in  Haiti.  
4.3.2 Visual Inspection with Acetic Acid or Lugol’s Iodine 
Visual  inspection  techniques  rely  on  visualization  of  the  cervix  under  bright  light  
at  least  one  minute  after  the  application  of  either  acetic  acid  or  Lugol’s  iodine,  which  
increase  the  color  contrast  between  healthy  tissue  and  areas  of  acetowhitening,  where  
cervical  dysplasia  may  exist.    In  low-­‐‑resource  settings,  these  techniques  come  with  both  
advantages  and  disadvantages  when  compared  to  other  screening  methods.      
The  main  advantage  of  visual  inspection  with  acetic  acid  (VIA)  over  cytology  is  
its  simplicity;  it  is  easy  for  health  workers  and  convenient  for  patients.    After  roughly  a  
week  of  training,  health  workers  from  a  variety  of  backgrounds  are  able  to  competently  
screen  women.    Results  are  nearly  immediate,  so  health  workers  can  diagnose  and  treat  
qualifying  patients  in  a  single  visit.    With  a  pooled,  average  sensitivity  of  80%  and  
specificity  of  92%,  based  on  meta-­‐‑analysis  of  26  studies  of  asymptomatic  women  in  
mostly  developing  countries,  VIA  generally  offers  improved  power  of  detection  when  
compared  to  cytology47;  however,  its  performance  varies  widely.        
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A  review  of  11  studies  conducted  by  Sankaranarayanan  and  her  colleagues  at  the  
International  Agency  for  Research  in  Cancer  (IARC)  in  2004  found  that  VIA’s  sensitivity  
and  specificity  were  highly  irregular  in  different  settings,  despite  commonalities  among  
patient  populations  and  clinician  training  methods.    For  example,  VIA’s  sensitivity  for  
CIN  III  in  Kolkata  and  Mumbai  was  58%,  while  in  Burkina  Faso  and  Guinea,  it  was  
90.3%.    Similarly,  specificity  for  CIN  III  varied  widely  between  Jaipur  and  Congo:  76.6%  
vs.  93.8%36.      
The  inherent  subjectivity  of  the  screening  process  explains  these  large  disparities.  
In  a  cross  sectional  study  from  India,  a  master  trainer  and  test  providers  only  agreed  in  
64.5%  (K  =  0.38)  of  diagnoses,  which  is  indicative  of  fair  agreement48.    To  improve  test  
performance,  some  have  suggested  that  quality  control  might  be  improved  by  using  
magnification  or  Lugol’s  Iodine  instead  of  acetic  acid.    Indeed,  VIA  with  magnification  
(VIAM  or  colposcopy)  is  considered  an  enhanced  version  of  VIA;  however,  cross-­‐‑
sectional  studies  from  India  and  South  Africa  have  suggested  that  magnification  does  
not  necessarily  improve  test  performance  over  naked  eye  assessment49,50.        On  the  other  
hand,  visual  inspection  with  Lugol’s  Iodine  (VILI)  does  garner  more  sensitive  (77.8  –  
98.0%)  and  specific  (73.0  –  91.3%)  results  than  VIA,  based  on  research  from  10  study  sites  
with  49,000  women34.      
Despite  VILI’s  apparent  advantages  over  VIA,  available  research  indicates  that  
only  the  latter  is  currently  practiced  in  Haiti.    In  2013,  DirectRelief  launched  a  pilot  VIA  
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program  in  Port-­‐‑au-­‐‑Prince  using  locally-­‐‑trained  clinicians,  screening  600  women  in  the  
first  week51.    To  date,  research  has  yet  been  published  on  the  program’s  performance.  
4.3.3 Clinician-Performed HPV Testing 
HPV  testing,  first  used  in  a  clinical  capacity  in  the  late  1980s,  is  a  relatively  
modern  screening  approach  that  has  gained  the  attention  of  researchers  and  public  
health  officials  for  its  successes  as  both  a  primary  and  supplemental  screening  method.    
Currently,  the  United  States  employs  reflex-­‐‑HPV  testing  in  women  with  pap  smears  that  
reveal  atypical  cells  of  undetermined  significance,  while  many  European  countries  are  
exploring  the  possibility  of  using  HPV  testing,  rather  than  cytology,  as  a  primary  
screening  tool52.    Unlike  other  approaches,  which  focus  on  the  visualization  of  
dyskaryotic  cells  at  either  the  microscopic  (cytology)  or  macroscopic  (colposcopy)  levels,  
HPV  testing  detects  the  causative  agent  of  cervical  cancer  sometimes  before  visible,  high  
grade  neoplasia  has  developed.    Through  polymerase  chain  reaction  (PCR)  or  Hybrid  
Capture  2  (hc2)  technologies,  viral  copies  of  DNA  in  cervical  samples  register  a  
“positive”  test  result  when  present  in  numbers  above  a  certain  threshold.    This  threshold  
can  be  adjusted  according  to  the  specificity  and  sensitivity  needs  of  the  population53.    
HPV  testing  is  especially  useful  in  LMICs  because  of  its  high  sensitivity,  negative  
predictive  value,  reproducibility,  and  quality  assurance6.    Compared  to  cytology  and  
VIA/  VIAM/  VILI,  HPV  tests’  sensitivity  for  detection  of  ≥	 CIN  II  is  markedly  elevated52.    
In  a  recent  meta-­‐‑analysis  of  22  studies  from  diverse  settings,  Cuzick,  Arbyn,  and  
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Sankarayanan  et  al.  (2008)  found  that  HPV  tests’  pooled  sensitivities  for  ≥	 CIN  II  and  ≥	 
CIN  III  were  93.1%  and  95.5%,  respectively54.    Since  that  meta-­‐‑analysis  was  conducted,  
several  more  studies  have  been  published  confirming  physician-­‐‑collected  cervical  
samples’  ability  to  detect  high  grade  disease  with  greater  than  90%  sensitivity  9,55,56.    
Research  from  developing  countries  exemplifies  the  benefits  of  HPV  tests’  
sensitivity.      Most  notably,  in  a  large,  cluster-­‐‑randomized  control  study  of  more  than  131  
thousand  asymptomatic,  Indian  women  from  497  villages  in  Osmanabad,  a  single  round  
of  HPV  testing  was  associated  with  significant  declines  in  the  rates  of  advanced  cervical  
cancer  and  cervical  cancer-­‐‑induced  mortality.    Contrastingly,  neither  VIA  nor  cytology  
evinced  positive  results  when  compared  to  the  control  cluster  of  13  villages  that  received  
the  standard  of  care.    Specifically,  the  age-­‐‑standardized  rate  of  invasive  cervical  cancer  
among  those  with  negative  results  from  VIA  or  cytology  was  four  times  as  high  as  the  
rate  among  HPV  negative  women6.    One  meta-­‐‑analysis  from  2008  concluded  that  
overall,  as  a  follow-­‐‑up  test  to  a  positive  pap  smear,  the  hc2  assay  is  14%  more  sensitive  
than  cytology,  but  equally  as  specific54.      This  disparity  in  sensitivity  is  explained  in  part  
by  HPV  tests’  ability  to  detect  pre-­‐‑cancer  and  cancer  at  earlier  stages  of  infection  than  
other  screening  methods57;  in  fact,  about  two-­‐‑thirds  to  three-­‐‑quarters  of  positive  HR  
HPV  cases  are  accompanied  by  pap  smears  showing  no  cellular  abnormalities58.      
In  addition  to  being  very  sensitive,  HPV  tests  are  also  strong  predictors  of  the  
absence  of  disease  when  compared  to  other  screening  methods.    A  high  negative  
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predictive  value  (NPV)  ensures  that  women  who  receive  negative  HPV  results  are  not  
only  negative  for  high-­‐‑grade  dysplasia,  but  also  are  unlikely  to  be  infected  with  HPV.    
Several  studies  from  around  the  world  have  compared  HPV  testing’s  NPV  to  VIA’s  and  
cytology’s,  and  each  has  concluded  that  HPV  testing  outperformed  the  rest.    Negative  
predictive  values  for  ≥	 CIN  II  consistently  range  between  95%  and  100%;  only  among  
HIV  positive  women  in  South  Africa  did  the  NPV  dip  slightly  to  94.1%,  though  this  
value  was  still  better  than  those  for  VIA  (87.5%)  or  cytology  (89.7%)56,59–61.    Because  of  the  
method’s  reliably  strong  negative  predictive  value,  many  researchers  have  suggested  
that  screening  intervals  could  be  lengthened  from  the  three  to  five  years  (used  in  
cytology)  to  six  to  ten  years62–64.    
High  sensitivity  and  negative  predictive  values  in  primary  screening  are  
particularly  important  in  developing  countries  where  women  have  infrequent  
interactions  with  health  systems,  and  therefore  may  only  undergo  screening  once  or  
twice  in  their  lifetimes.    Additionally,  the  extended  screening  interval  could  significantly  
reduce  physicians’  patient  burden  and  funders’  financial  burden.    Utilization  of  
QIAGEN’s  CareHPV  assay,  a  cheaper,  easier,  but  equally  accurate  alternative  to  hc2  that  
gives  results  in  three  hours,  could  also  help  drive  down  costs53.  
HPV  testing’s  reproducibility  augments  these  characteristics  by  providing  
superior  quality  assurance  to  other  methods;  a  multi-­‐‑center,  multi-­‐‑day  study  found  that  
hc2  test  results  agree  99.5%  of  the  time  (Kappa  =  0.990)6.    The  three  participating  
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laboratories  were  given  identical  reproducibility  panels  of  HPV  DNA  targets,  HPV  
positive  clinical  specimens,  and  HPV  negative  clinical  specimens.    100%  of  expected  
positive  specimens  returned  positive  results  and  99%  of  expected  negative  specimens  
returned  negative  results14.      
Using  specified  calibrators  and  an  HR  HPV  control  sample  of  5  pg/mL  (500,000  
copies/mL)  of  cloned  HPV  16  DNA  and  carrier  DNA  ensures  each  test’s  quality.    Digene  
(now  QIAGEN)  computer  software,  rather  than  human  eyesight,  determines  the  
calibrators’  and  controls’  positions  on  the  microplate14.    With  the  help  of  advanced  
technology,  training  technicians  to  perform  HPV  testing  is  less  demanding  than  training  
cytologists.      
   For  all  its  benefits,  HPV  testing  can  still  be  a  challenge  to  implement  in  some  
low-­‐‑resource  settings,  for  a  couple  of  reasons:  namely,  its  utilization  of  clinicians  and  
need  for  existing  infrastructure.    While  individuals  who  complete  short  training  courses  
can  perform  hc2  testing,  physicians  or  nurses  are  required  to  collect  cervical  specimens.    
With  a  need  for  high  coverage  rates,  reliance  upon  already  over-­‐‑burdened  clinicians  for  
screening  is  challenging  in  countries  like  Haiti,  where  the  physician  to  population  ratio  
is  3/  10,00065.    This  led  us  to  test  the  hypothesis  that  self-­‐‑performed  vaginal  sampling  




4.4 Self-Performed HPV Testing  
Self-­‐‑screening  for  HPV  and  other  sexually-­‐‑transmitted  infections  was  first  
suggested  in  the  late  1970s,  but  has  only  recently  gained  global  traction  as  an  alternative  
testing  method  for  women  in  medically  underserved  areas45.    Interest  has  burgeoned  as  
research  has  demonstrated  self-­‐‑screening’s  strong  diagnostic  performance  relative  to  
other  methods  and  its  widespread  acceptability  among  diverse  populations  of  women.    
While  the  sensitivity  of  self-­‐‑collected  specimens  is  high  using  most  tools  (cytobrushes,  
cervicovaginal  lavages,  tampons,  and  Dacron  swabs),  studies  have  shown  that  cotton  
swabs  are  infeffective66,67.    Brushes  appear  to  have  the  greatest  sensitivity  of  detecting  ≥  
CIN  II,  and  are  therefore  the  standard  tools  that  accompany  QIAGEN’s  cervical  sampler  
kits.  
4.4.1 Variations in Tools, Techniques, and Testing 
At  present,  there  are  no  standardized  instructions  for  self-­‐‑sampling,  which  may  
explain  some  of  the  variations  in  sensitivities  and  specificities  observed  in  different  
studies.    Some  postulate  that  sample  accuracy  is  dependent  upon  proximity  to  the  
cervix;  others  focus  on  the  size  of  the  sample  collected,  which  might  be  influenced  by  
position,  instrument,  or  the  number  of  rotations  of  the  sampling  device9,10.    Among  
women  reluctant  to  collect  their  own  samples,  concern  over  incorrectly  performing  the  
test  is  the  most  commonl  complaint10.    With  public  health  officials  increasingly  
considering  self-­‐‑sampling  as  a  viable  screening  tool,  particularly  in  rural  and  
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impoverished  areas,  scientists  and  policy-­‐‑makers  ought  to  develop  and  approve  
universal  instruments  and  instructions  for  their  use.  
There  is  also  some  disagreement,  or  at  least  variation,  among  the  cut-­‐‑off  points  
for  positivity  on  the  most  widely  used  assays:  hc2  and  CareHPV.    Some  researchers,  
using  ROC  curves,  have  adjusted  the  relative  light  units’  (RLU)  proportion  to  the  cut-­‐‑off  
(CO)  value  according  to  populations’  needs,  either  raising  or  lowering  the  value  from  
QIAGEN’s  prescribed  “1.0”53,68.    These  adjustments  allow  scientists  to  address  one  of  the  
main  complaints  against  HPV  testing:  its  diminished  specificity  relative  to  cytology.    By  
increasing  the  RLU/CO,  specificity  can  be  increased  to  exclude  samples  with  weakly  
positive  signal  strengths,  and  the  opposite  can  be  done  to  increase  sensitivity69,70.    Public  
health  officials,  who  must  weigh  the  consequences  of  increasing  physicians’  patient  
loads  or  denying  colposcopies  to  women  who  may  never  be  screened  again,  can  benefit  
from  this  flexibility.  
Regardless  of  variations  in  methodologies,  studies  consistently  report  that  self-­‐‑
screening  is  both  diagnostically  strong  and  well-­‐‑liked  by  participants  in  home  and  
clinical  settings10,49,71–73.  
4.4.2 Diagnostic Performance 
The  findings  from  a  number  of  studies  from  around  the  world  have  contributed  
to  the  understanding  that  vaginal  self-­‐‑sampling  is  a  diagnostically  capable  method  of  
cervical  cancer  screening  when  compared  to  alternatives.    In  a  review  of  28  studies  from  
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1992  to  2012,  Snijders  et  al.  (2013)  cogently  presented  the  evidence  for  this,  though  not  
all  28  were  included  for  consideration  in  this  discussion.    Studies  that  calculated  
sensitivity  and  specificity  on  the  basis  of  available  histology—  only  from  women  with  
positive  HPV  tests  or  abnormal  paps—  did  not  account  for  verification  bias  by  randomly  
sampling  a  handful  of  HPV-­‐‑negative  or  “normal  pap”  patients.    Therefore,  only  research  
papers  that  addressed  this  bias  through  random  sampling  or  universal  application  of  a  
reference  standard  are  mentioned  hereafter.      
Of  five  studies  that  examined  the  accuracies  of  self-­‐‑collected  specimens  to  
physician-­‐‑performed  pap  smears,  three  of  them  showed  that  the  former  was  better  able  
to  detect  ≥  ASCUS  or  ≥  LSIL  than  the  latter55,56,74.    In  these  cases,  the  pooled  sensitivity  for  
self-­‐‑screening  was  86.3%,  compared  to  cytology’s  79.6%.    Including  the  two  studies  in  
which  cytology  (one  conventional  and  one  liquid-­‐‑based)  was  more  sensitive  than  self-­‐‑
screening,  the  overall  pooled  sensitivity  for  the  five  studies  was  84.5%  for  HPV  testing  
and  85.2%  for  cytology  10,75,76.  
Interestingly,  according  to  the  five  studies  of  referral  and  healthy  populations  
highlighted  in  Snijders  et  al.  (2013),  HPV  testing  and  pap  smears  performed  equally  well  
in  specificity  for  ≥  CIN  I;  the  pooled  specificity  was  69.4%  for  HPV  self-­‐‑screening  and  
67.3%  for  cytology.    It  is  possible  that  both  measures  of  diagnostic  performance  were  
comparable  because  low-­‐‑grade  disease  was  used  as  the  detection  target  rather  than  
high-­‐‑grade  disease,  or  because  the  prevalence  of  disease  was  low  in  the  tested  
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populations.  When  researchers  have  established  ≥  CIN  II  as  the  target  for  detection,  self-­‐‑
samples’  sensitivities  have  been  mostly  recorded  in  the  90s,  and  even  as  high  as  100%,  
while  specificities  are  slightly  lower,  typically  ranging  between  70  and  90%  for  healthy  
patients,  and  50  to  70%  for  referral  patients10,77,78.      
Relative  to  clinician-­‐‑performed  HPV  testing  –  the  most  sensitive  screen  for  high-­‐‑
grade  disease  available—  self-­‐‑sampling  fares  remarkably  well.    To  measure  vaginal  
samples’  diagnostic  ability  against  cervical  samples’,  researchers  often  compare  the  
concomitant  samples  using  percent  agreement  and  an  accompanying  Kappa  statistic,  K.    
Percent  agreements  evince  concordance  while  Kappa  statistics  describe  the  strength  of  
that  concordance  (on  a  scale  from  -­‐‑1  to  1)  relative  to  what  one  would  expect  to  garner  
from  chance  alone79.    In  the  past  decade,  several  meta-­‐‑analyses  have  examined  dozens  of  
studies  comparing  the  diagnostic  performance  of  self-­‐‑sampling  to  physician  sampling,  
and  each  analysis  has  concluded  that  the  preponderance  of  studies  demonstrate  that  the  
tests  bear  high  percentages  of  agreement  with  moderate  (0.41  –  0.60)  to  good  (0.61  –  0.80)  
Kappa  values80–83.      
Importantly,  results  appear  uniformly  positive  in  both  high-­‐‑income  and  middle-­‐‑  
to  low-­‐‑income  countries,  and  in  both  healthy  and  referral  populations.    In  two  studies  
from  Munich  in  1999  and  2004,  concordance  rates  between  self-­‐‑collection  and  physician-­‐‑
collection  were  83  and  92%  (K=0.71),  respectively64,84.    Researchers  found  that  cases  of  
test  disagreement  were  mostly  due  to  vaginal  positivity  and  cervical  negativity.    
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Hillemanns  et  al.  (1999)  demonstrated  that  while  self-­‐‑collected  and  clinician-­‐‑collected  
samples  were  equally  sensitive  (92%)  for  high-­‐‑grade  disease,  the  former  was  more  
sensitive  at  detecting  histologically-­‐‑confirmed  CIN  I.    Research  from  South  America,  
Asia,  and  Africa  has  produced  similar  results  with  Kappa  values  all  greater  than  0.7  56,85–
87.    In  women  greater  than  18  years  of  age  attending  a  community  health  center  in  
Gugulathu,  South  Africa,  Jones  et  al.  (2007)  only  garnered  such  strength  of  agreement  
when  using  the  Roche  Reverse  Line  Blot  Assay  (RLBA)  (Roche  Molecular  Systems  Inc.,  
Branchburg,  NJ,  USA)  to  determine  results.    Using  swabs  as  the  collection  device  and  
RLBA  as  the  testing  technology,  vaginal  and  cervical  samples  showed  89%  concordance  
(K=0.75).    Using  hc2  assay,  swabs  were  81%  concordant  (K=0.61)  and  tampons  were  82%  
concordant  (K=0.55).    These  results,  while  all  indicative  of  moderate  to  good  agreement  
between  HPV  tests,  evince  that  many  variables,  including  technology,  can  affect  
diagnostic  performance.  
4.4.3 Age and HPV Prevalence 
Some  research  suggests  that  the  relationship  between  age  and  HPV  DNA  test  
diagnostics  is  mediated,  at  least  in  part,  by  varying  HPV  prevalence  rates  among  
different  age  cohorts11,13,88–92.    In  two  large,  population-­‐‑based  studies  in  China  (n  =  28,848  
and  n  =  13,004),  researchers  revealed  that  in  both  physician-­‐‑collected,  cervical  specimens  
and  self-­‐‑collected,  vaginal  specimens,  specificity  decreased  with  increasing  age;  those  
younger  than  35  years  old  had  the  highest  specificity91,93.    Other  reports  from  Europe  and  
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North  America  contradict  these  results,  demonstrating  greater  specificity  in  older  
women94.    These  incongruent  patterns  are  possibly  reflective  of  disparate  age-­‐‑related  
prevalence  rates  in  the  two  regions:  HPV  peaks  only  in  young  women  in  North  America  
and  Europe90,  but  peaks  both  in  young  and  middle-­‐‑aged  women  in  China93.      Global  
disparities  can  be  quite  significant;  in  fact,  a  large,  cross-­‐‑sectional  study  of  15  areas  from  
four  continents  indicates  that  age-­‐‑specific  prevalence  curves  sometimes  vary  by  an  order  
of  magnitude  between  locations.      
Recently,  Elkins  et  al.  (2013)  substantiated  previous  evidence  linking  patient  age  
with  test  performance  while  displaying  the  importance  of  RLU/CO  values  in  rendering  
HPV  diagnoses.    Using  359  cervicovaginal  samples  that  produced  initially  equivocal  hc2  
test  results  (RLU/CO  between  1  and  2.5  pg/mL),  researcher  found  that  re-­‐‑test  results  
were  dependent  on  age.    As  age  increased,  the  number  of  true  positives  (RLU/CO  ≥  1)  
decreased:  93.3%  of  15  –  29  year-­‐‑olds  received  secondary  positive  diagnoses  compared  
to  71.9%  of  women  50  and  older13.    Another  study  of  women  with  weakly  positive  hc2  
tests  revealed  that  when  the  RLU/CO  value  was  set  anywhere  between  1  and  10  pg/mL,  
no  cases  of  CIN  II  or  greater  were  discovered  in  women  over  5092.  
Certain  low-­‐‑risk  (LR)  HPV  strains,  that  are  known  to  sometimes  cross-­‐‑react  with  
the  hc2  assay  to  produce  false  positives,  also  fluctuate  in  prevalence  by  age14.    These  
geographic  inconsistencies  in  age-­‐‑related  prevalence  rates  and  test  performances  
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underscore  the  need  for  age-­‐‑stratified  data  in  Haiti,  as  they  could,  among  other  things,  
inform  RLU/CO  adjustments  and  recruitment  targets.  
4.4.4 Cost 
While  most  HPV  testing  is  relatively  expensive  and  requires  skilled  laboratory  
services  that  are  uncommon  in  LMICs,  vaginal  self-­‐‑screening  in  Haiti  may  prove  to  be  
cheaper  than  alternatives  for  several  reasons.    First,  QIAGEN  and  PATH  recently  
developed  a  DNA  assay  called  “CareHPV”  that  promises  to  be  a  cheaper  and  simpler  
alternative  to  the  currently  available  commercial  assays  53.    Second,  QIAGEN  and  Family  
Health  Ministries  are  in  the  process  of  training  Haitian  lab  technicians  and  building  
pathology  labs  in  Port-­‐‑au-­‐‑Prince  and  Leogane  that  are  intended  to  accommodate  the  
HPV  testing  needs  of  thousands  of  women.    Third,  recent  data  from  five  different  
developing  countries  evinced  that  clinician-­‐‑performed  HPV  DNA  testing  is  more  cost-­‐‑
effective  than  conventional  cytology  for  preventing  cervical  cancer  in  those  settings.    
With  a  high  sensitivity  and  negative  predictive  value,  screening  for  HPV  allows  for  
greater  time  intervals  between  sampling.    Self-­‐‑screening,  if  equally  as  sensitive  as  
clinician-­‐‑performed  screening  in  Haiti,  could  also  reduce  sampling  frequency  and  
overall  cost  relative  to  cytology95,96.      
4.4.4 Cultural Acceptability and Attendance Rates 
In  addition  to  its  diagnostic  and  potential  financial  advantages  over  cytology  and  
VIA,  HPV  self-­‐‑screening  is  also  widely  accepted  and  preferred  over  more  intrusive  
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methods  by  patients.    Indeed,  women  from  urban  and  rural  settings,  rich  and  poor  
countries  universally  respond  positively  to  self-­‐‑testing.    Data  from  around  the  world  
have  shown  comfort  or  acceptability  rates  ranging  from  82%  in  Kenya  to  98%  in  Mexico  
45,64,71,72,84,97.    Preference  over  other  methods  is  also  strong  in  a  variety  of  settings:  97%  of  
German  internal  medicine  outpatients  and  93%  of  Greek  gynecological  patients  
expressed  partiality  towards  self-­‐‑screening  rather  than  cytology.    How  these  high  
approval  ratings  will  impact  attendance  rates  is  still  largely  unknown,  however.      
According  to  a  comprehensive  meta-­‐‑analysis  of  the  literature  from  1992  to  2012,  
only  9  studies  have  measured  the  impact  of  self-­‐‑screening  on  attendance  rates  among  
non-­‐‑attendees  of  regular  screening  programs.    These  studies,  all  completed  in  developed  
countries,  showed  improvements  in  attendance  (typically  by  mailing-­‐‑in  samples)  of  
between  8.7%  (in  Italy)  and  39.1%  (in  Sweden)10.    Although  similar  statistics  do  not  exist  
for  programs  in  LMICs,  one  study  from  rural  Brazil  provides  encouraging  evidence  for  
community  health  workers’  ability  to  increase  screening  coverage  among  non-­‐‑attendees.    
After  just  one  day  of  training,  community  health  workers  (CHWs)  successfully  recruited  
878  women  by  going  door-­‐‑to-­‐‑door.    According  to  Holanda  et  al.  (2006),  100%  of  women  
approached  by  CHWs  agreed  to  perform  an  HPV  test,  and  impressively,  100%  of  
women  went  into  the  clinic  a  week  later  to  undergo  follow-­‐‑up  testing87.    Training  CHWs  
in  Haiti  to  match  this  success  could  allow  for  a  miraculous  reduction  in  disease  through  
increased  screening  coverage.  
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While  research  has  not  yet  been  published  on  the  cultural  acceptability  or  
preferences  of  self-­‐‑screening  in  Haiti  itself,  data  collected  from  Haitian  immigrant  
women  (97%  of  whom  were  foreign-­‐‑born)  in  Little  Haiti,  Miami,  suggests  the  method  
would  be  well-­‐‑tolerated.    Kreyol-­‐‑speaking,  female  community  health  workers  (CHWs)  
of  Haitian  descent  recruited  adult  Haitian  women  from  various  venues  where  they  
established  a  later  meeting  time  to  perform  the  tests  in  places  of  the  participants’  
choosing  (usually  their  homes  or  friends’  homes).    Of  the  246  who  participated,  242  gave  
adequate  specimens  after  receiving  verbal  and  pictorial  instructions  from  a  CHW.    95.1%  
of  women  found  the  self-­‐‑collection  device  (“Fournier,”  which  has  the  appearance  of  a  
tampon)  easy  to  use,  and  97.6%  found  it  comfortable  to  use  at  home.    Additionally,  
98.4%  of  participants  responded  that  they  would  recommend  this  test  to  friends  and  
family  members,  and  87%  said  they  preferred  it  to  pap  smears45.  
To  explain  this  positive  response,  the  researchers  behind  the  study  cited  
anecdotal  evidence  and  previous  ethnographic  fieldwork.    Their  sources  attribute  the  
overwhelming  acceptance  of,  and  preference  for,  self-­‐‑sampling  to:  the  lack  of  pain  
experienced,  cultural  conceptions  of  modesty  and  privacy,  discomfort  with  male  
clinicians,  and  concern  about  vaginal  tone.    Maintenance  of  vaginal  tone  or  tightness  is  
especially  important  to  Haitian  women,  who  cleanse  themselves  multiple  times  a  day  as  
part  of  the  effort  (Barbee  et  al.  (2010)  believe  this  practice  to  be  the  source  of  
inflammation  seen  in  over  45%  of  Haitian  immigrants’  pap  smears).    Some  women  fear  
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that  introducing  a  speculum  into  the  vagina  to  perform  VIA  or  pap  test  could  make  
them  too  “open,”  causing  their  partners  to  suspect  infidelity  or  express  dissatisfaction  
during  intercourse98.    This  testimony  conveys  the  complexity  of  selecting  an  appropriate  
cervical  cancer  prevention  strategy  in  Haiti;  while  diagnostic  performance  and  cost  may  
be  important  considerations  for  clinicians  and  government  officials,  cultural  beliefs  are  













5. Materials and Methods 
 
5.1 Study Setting 
Two  clinics  in  Port-­‐‑au-­‐‑Prince,  Haiti  served  as  the  testing  locations  for  this  study:  
Family  Health  Ministries’  Blanchard  Clinic  and  Centre  Haitien  d’Investigation  de  
Traitement  Avancé  de  L'ʹInfertilité  (CHITAI).    The  overwhelming  preponderance  of  
participants  were  tested  and  treated  at  the  modest,  two-­‐‑storied  Blanchard  Clinic,  which  
is  nestled  on  the  grounds  of  a  compound  that  also  includes  a  primary  school,  Protestant  
Church,  and  guest  quarters  for  visiting  missionaries  and  medical  teams.    The  
surrounding  neighborhood,  Terre  Noire,  is  one  of  the  poorest  areas  within  the  capital  
city.  Contrastingly,  CHITAI  is  a  private,  fertility  clinic  that  typically  caters  to  patients  




5.2 Research Design 
From  May  2012  to  April  2013,  1836  women  participated  in  a  two-­‐‑part,  cross-­‐‑
sectional  study  conducted  at  two  clinics  in  Port-­‐‑au-­‐‑Prince,  Haiti.    The  first  part  of  the  
study,  which  served  as  the  basis  for  the  research  presented  in  this  document,  consisted  
of:  1)  self-­‐‑performed  and  clinician-­‐‑performed  HR  HPV  screening;  2)  visual  inspection  
with  acetic  acid  magnified  (colposcopy);  and  3)  cervical  biopsy  of  precancerous  lesions.    
As  of  April  2013,  colposcopies  and  biopsies  are  ongoing.    The  second  part  of  the  study,  
which  is  also  ongoing,  examines  the  accuracy  of  colposcopy.    The  target  sample  size  
(1845)  was  powered  to  answer  the  research  questions  in  both  parts  of  the  study.      
QIAGEN  (formerly  Digene  Corporation,  Gaithersburg,  Maryland),  the  Center  for  
Aids  Research  (CFAR),  and  Duke  University  (Durham,  North  Carolina)  (AI064518)  
provided  materials  and  funding,  respectively.    The  study  was  approved  by  both  
American-­‐‑based  (Duke  University  Medical  School)  and  Haitian-­‐‑based  (Family  Health  
Ministries)  Institutional  Review  Boards  to  ensure  cross-­‐‑cultural  ethical  standards  were  
met.    
  
5.3 Recruitment and Sampling 
Women  were  recruited  through  clinic  referral  and  word-­‐‑of-­‐‑mouth.    The  clinic  
administrator  at  Samaritan’s  Purse  Clinic  on  Haiti  Outreach  Ministries’  Cite  Soleil  
Compound  regularly  advertised  the  study  to  her  staff  and  patients,  and  helped  
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coordinate  weekly,  free  transportation  from  the  compound  to  Blanchard  Clinic  for  
interested  participants.    Additionally,  members  of  a  cancer  survivors’  support  group,  
Groupe  de  Support  Contre  le  Cancer  (GSCC),  encouraged  participation  by  informing  
friends  and  church  audiences  of  the  study’s  existence  and  potential  importance  to  
Haitian  women’s  health.    Occasionally,  Blanchard  clinic  staff  recruited  participants  from  
Terre  Noire,  the  neighborhood  in  which  Blanchard  Clinic  resides,  by  speaking  through  a  
megaphone  and  addressing  passers-­‐‑by.    The  staff  at  CHITAI  recruited  participants  
through  conversation  during  their  regular  gynecological  appointments.      
These  techniques  helped  successfully  recruit  and  enroll  1836  women  who  met  
the  inclusion  criteria.    Specifically,  women  between  the  ages  of  25  and  65  years  old  who  
had  engaged  in  vaginal  intercourse  at  least  once  during  their  lifetimes  were  included  in  
the  study.    Exclusion  criteria  were  current  pregnancy,  prior  hysterectomy,  or  active  
menstruation.    Women  who  came  to  the  clinic  while  on  their  periods  were  asked  to  
return  for  testing  after  a  couple  of  weeks.      
 
5.4 Education and Consent  
At  Blanchard  clinic,  a  trained  health  worker  educated  the  women  as  a  group  in  
issues  related  to  prevention,  transmission,  and  treatment  of  cervical  cancer  and  HIV.    
The  danger  and  likelihood  of  HIV-­‐‑HPV  co-­‐‑infection  was  discussed.    Study  protocol  and  
procedure  was  described,  including  how  HPV  and/or  HIV  positive  cases  would  be  
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handled.    Participants  were  given  pamphlets  printed  in  Haitian  Kreyol  that  highlighted  
key  facts  from  the  lecture.    Informational  posters  also  decorated  the  waiting  room.    At  
CHITAI,  participants  were  similarly  educated  and  provided  with  pamphlets,  although  
they  interacted  with  health  workers  individually  rather  than  as  a  group.  
Following  education,  participants  signed  identical  Haitian  Kreyol  and  English  
consent  forms  in  private  rooms.    Women  who  could  not  write  their  names  gave  their  
consent  by  signing  with  “X”s.    Health  workers  also  obtained  demographic  information  
and  healthy  histories,  which  they  recorded  on  forms  with  a  randomly  pre-­‐‑assigned  
patient  ID  numbers.    Repeat  patients  kept  their  previous  ID  numbers  for  medical  record-­‐‑
keeping  purposes.    All  patients  were  given  blue  ID  cards  on  which  nurses  later  recorded  
the  dates  on  which  patients  ought  to  return  to  receive  HPV  results.    The  blue  color  of  the  
cards  signified  participation  in  this  study,  contrasting  the  white  ID  cards  used  for  non-­‐‑
participants  (regular  gynecological  patients).  
 
5.5 Clinical Procedures and Materials 
With  few  exceptions,  participants  completed  three  tests  –  a  self-­‐‑collected  HR  
HPV  screen,  a  health  worker-­‐‑collected  HR  HPV  screen,  and  a  rapid  HIV  test—  in  one  
clinic  visit.    All  tests  were  completed  using  aseptic  techniques,  and  at  a  level  of  privacy  
considered  appropriate  in  Haitian  culture.    HR  HPV  positive  patients  returned  on  a  
prescheduled,  later  date  for  follow-­‐‑up  investigation  with  colposcopy  and  biopsy.    They  
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were  treated  with  cryotherapy  in  the  clinic  or  referred  elsewhere  for  other  treatment,  as  
needed.    
5.5.1 Self-Collected and Health Worker-Collected HPV Tests 
Vaginal  and  cervical  samples  were  taken  using  conic-­‐‑shaped  brushes—  the  
digene  Cervical  Brush  (QIAGEN,  formerly  Digene  Corporation,  Gaithersburg,  
Maryland).    First,  nurses  instructed  the  patients  to  rotate  the  brush  three  times  
counterclockwise  in  their  vaginas.    Being  careful  to  avoid  contamination,  the  brush  was  
placed  in  a  vial  with  digene  Specimen  Transport  Medium  (STM)  for  storage  and  
transport.    Vaginal  specimens  were  marked  with  blue  patient  ID  stickers  and  the  testing  
date.    Patients  were  then  asked  to  lie  in  the  dorsal  lithotomy  position  for  the  second  
screen.    After  removing  excess  mucus  from  the  cervical  os  and  surrounding  ectocervix  
with  a  cotton  swab,  a  physician  or  nurse  took  a  cervical  sample  by  inserting  a  clean  
brush  1  to  1.5  cm  into  the  cervical  os  and  rotating  it  three  times  counterclockwise.    The  
sample  was  placed  in  an  STM-­‐‑filled  vial  labeled  with  a  white  patient-­‐‑ID  sticker  and  the  
date.      
5.5.2 Rapid HIV Test 
Rapid  HIV  tests  were  performed  using  Alere  DetermineTM  HIV-­‐‑1/2  Tests  (Alere  
Medical  Co.  Ltd.,  Chiba-­‐‑ken,  Japan).    The  colloidal  gold-­‐‑enhanced,  
immunochromatographic  assay  detected  HIV  antibodies  in  whole  blood  taken  from  
finger  pricks.    Safety  lancets  were  used  to  puncture  alcohol-­‐‑disinfected  skin,  and  
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heparinized  capillary  tubes  (Chase  Scientific  Glass  Inc.,  Rockwood,  TN,  USA)  were  used  
to  collect  the  blood  and  dispense  it  on  the  test  strip’s  sample  pad.    Two  drops  of  buffer  
solution  (Chase  Scientific  Glass  Inc.,  Rockwood,  TN,  USA)  were  immediately  added  to  
the  sample  pad  to  enhance  capillary  action.    Tests  were  laid  flat  for  fifteen  minutes  to  
allow  the  blood-­‐‑buffer  solution  time  to  migrate  to  the  top  of  the  assay  strip.  
5.5.3 Colposcopy and Biopsy 
Trained  physicians  performed  colposcopies  and  biopsies  on  HR  HPV  positive  
patients.    Visual  inspection  with  magnification  of  precancerous  lesions  was  performed  
after  applying  acetic  acid  to  the  cervix.    A  single  biopsy  was  taken  with  Kevorkian  
Biopsy  Specimen  Forceps  (Instrumed  (PVT)  Ltd.,  Sialkot,  Pakistan)  from  a  visible  lesion  
whose  location  was  recorded  in  the  patient’s  medical  record.    In  accordance  with  part  
two  of  the  ongoing  study  (CFAR  AI064518),  the  first  50  women  with  HR  HPV  positive  
tests  were  randomly  biopsied  in  each  quadrant  of  their  cervixes,  regardless  of  the  
presence  of  lesions.    Specimens  were  stored  in  vials  of  formaldehyde  with  parafilm-­‐‑
secured  lids  to  prevent  leakage  during  shipment  to  the  diagnostic  facility.  
 
5.6 Diagnostics  
5.6.1 Self-Collected and Health Worker-Collected HPV Tests 
  Weekly,  de-­‐‑identified  HR  HPV  brush  samples  were  collected  from  participating  
clinics  and  mailed  to  a  pathology  lab  in  America  for  diagnosis.    QIAGEN  tested  vaginal  
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and  cervical  brush  samples  for  13  high-­‐‑risk  HPV  genotypes  (16,18,  31,  33,  35,  39,  45,  51,  
52,  56,  58,  59,  and  68)  using  the  Hybrid  Capture  ®  2  High-­‐‑Risk  HPV  DNA  Test  TM  (hc2).    
In  the  hc2  nucleic  hybridization  assay,  HR  HPV  DNA  hybridizes  with  specific  RNA  
probes.    Hybrids  are  captured  and  immobilized  by  antibodies  on  a  microplate  and  then  
reacted  with  alkaline-­‐‑phosphatase  conjugated  antibodies  specific  to  HR  HPV  DNA.    
Because  multiple  alkaline-­‐‑phosphatase  conjugated  antibodies  bind  to  a  single  HR  HPV  
hybrid  molecule,  the  target  molecules  have  substantially  amplified  signals.    As  the  
bound  enzymes  cleave  from  their  substrates,  light  is  emitted.    The  Digene  Microplate  
Luminometer  2000  TM  measures  the  intensity  of  the  light  in  relative  light  units  (RLU),  
which  convey  the  presence  or  absence  of  HR  HPV  DNA  in  the  sample.    QIAGEN  
designates  an  RLU  cut-­‐‑off  (RLU/CO)  value  of  one  for  HR  HPV  DNA;  less  than  one  
indicates  its  absence  (a  negative  test  result)  and  equal  to  or  more  than  one  indicates  its  
presence  (a  positive  test  result).    The  RLU/CO  is  defined  by  the  average  of  the  RLU  of  
the  Positive  Calibrator  multiplied  by  the  correction  factor.      
5.6.2 Rapid HIV Test 
Within  15  minutes  of  test  completion,  a  trained  health  worker  was  able  to  make  a  
diagnosis  for  HIV.    A  colored  control  band  appeared  on  the  lower  end  of  the  test  strip  
regardless  of  the  test  result  to  indicate  that  the  colloidal  gold  conjugate  assay  was  
functioning.    The  appearance  of  a  second  colored  band  higher  up  on  the  test  strip  
denoted  a  positive  result  (100%  sensitivity  relative  to  enzyme  immune  assay  (EIA)  
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results).    Positive  test  results  were  confirmed  with  a  repeat  test  on  the  same  day.    The  
absence  of  a  test  band  denoted  a  negative  result  (99.75%  specificity  relative  to  EIA  
results).  
5.6.3 Biopsy 
Approximately  every  three  to  four  weeks,  biopsy  specimens  were  mailed  to  
PathForceDx  (Silverdale,  WA,  USA)  for  diagnosis.    PathForceDx  outsourced  the  
technical  component  of  its  analysis  to  Pathology  Associates  Kitsap  County  (Bremerton,  
WA,  USA).    A  whole  slide-­‐‑scanner  (Leica  SCN400  Scanner)  prepared  colorful,  3D,  digital  
images  of  the  pathology  slides  that  were  uploaded  to  a  secure  cloud  workspace.    ABP  
board-­‐‑certified  pathologists  examined  the  histopathologic  specimens  using  the  Simagis  
Live  Slide  Image  Viewer  and  reported  diagnoses  as  either  normal,  HPV  cytopathic  
effect,  CIN  I,  CIN  II,  CIN  III  or  invasive  cancer.  
 
5.7 Follow-Up and Treatment  
After  completing  the  HR  HPV  tests,  nurses  informed  participants  verbally,  and  
in  writing,  of  the  dates  on  which  they  ought  to  return  for  their  results.    The  health  
worker  performing  the  HIV  tests  reiterated  the  importance  of  returning  for  HR  HPV  
results  on  the  scheduled  dates.    A  health  worker  discreetly  informed  women  of  their  test  
results  individually.    HR  HPV  negative  women  were  asked  to  return  for  follow-­‐‑up  
screening  in  a  year,  while  HR  HPV  positive  women  were  scheduled  for  colposcopy  and  
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biopsy  within  the  next  few  months.    Nurses  contacted  women  who  failed  to  return  for  
results  and/  or  follow-­‐‑up  appointments  within  approximately  a  week  of  the  missed  
appointment.        
Because  loss  to  follow-­‐‑up  after  HPV  screening  is  a  known  problem  in  Haiti—
reportedly  50%  at  Family  Health  Ministries’  Leogane  Clinic5—a  “see-­‐‑and-­‐‑treat”  protocol  
was  offered  to  women  with  pre-­‐‑cancerous  lesions  who  were  felt  to  be  at  risk  of  not  
returning.    Haitian  doctors  are  generally  more  liberal  than  American  doctors  in  using  
cryotherapy  to  treat  low-­‐‑grade  disease  because  of  their  concern  that  many  patients  may  
be  screened  only  once  in  their  lifetimes.      Patients  diagnosed  with  cancer  were  referred  
to  local  hospitals  for  staging,  surgery,  chemotherapy,  palliative  care  or  possible  referral  
out  of  the  country  for  radiation  therapy.    Financial  assistance  for  some  patients  was  
secured  through  GSCC.    The  flow  chart  in  Appendix  A  outlines  FHM’s  cervical  cancer  
screening  and  treatment  protocol.  
HIV  positive  women  (confirmed  with  a  repeat  test  during  the  same  visit)  
received  post-­‐‑test  counseling  from  trained  health  workers  immediately  after  results  
were  available—typically  within  15  to  30  minutes.    Women  were  referred  to  local  
organizations—Groupe  Haitien  d'ʹÉtude  du  Sarcome  de  Kaposi  et  des  Infections  
Opportunistes  (GHESKIO)  and  Fondation  pour  la  Santé  Reproductrice  et  l’Education  




United  States’  Federal  Privacy  Regulations  provide  safeguards  for  privacy,  
security,  and  authorized  access.    As  required  by  these  laws,  study  records  with  
identifying  patient  information  have  been  kept  private.    Family  Health  Ministries  linked  
study  records  to  patient  records  using  uniquely  assigned  code  numbers.    The  key  to  
deciphering  the  code  is  stored  in  a  locked  file  in  the  research  office  at  FHM’s  
headquarters  in  North  Carolina.      
Study  participants  are  aware  that  representatives  of  the  National  Institutes  of  
Health  or  Duke  University  Health  System’s  Institutional  Review  Board  may  review  their  
records  to  ensure  adherence  to  federal  or  state  regulations.    All  study-­‐‑related  records  
will  be  retained  by  FHM  for  at  least  six  years  after  the  study’s  completion.
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6. Data Analysis 
1845  women  completed  both  vaginal  and  cervical  HR  HPV  screens,  though  only  
1836  were  used  in  analysis  because  nine  women’s  study-­‐‑specific  consent  forms  could  not  
be  located.    Descriptive,  demographic  statistics  were  generated  using  all  available  data,  
including  statistical  outliers.    For  example,  the  calculation  for  mean  age  of  sexual  debut  
included  three  women  whose  ages  of  first  sexual  encounters  were  recorded  as  4,  8,  and  
9.    At  the  time  of  publication,  cervical  biopsy  results  were  available  for  106  women.    
When  all  biopsies  have  been  performed,  and  tissue  samples  diagnosed,  the  dataset  will  
include  histopathological  information  for  445  women.    
Overall  prevalence  rates  were  calculated  for  HIV,  vaginal  and  cervical  HR  HPV,  
and  level  of  disease  observed  in  biopsy  samples.    Biopsy  results  among  HR  HPV  
positive  patients  were  characterized  as  HPV  cytopathic  effect,  CIN  I,  CIN  II,  CIN  III,  and  
invasive  cancer.    HR  HPV  prevalence  rates  were  also  stratified  by  age  quartiles  and  
tested  for  significance  of  difference  using  chi-­‐‑square  tests.  Participants  were  considered  
“HPV  positive”  if  they  had  at  least  one  HR  HPV  positive  test  result—either  vaginal,  
cervical,  or  both.    
Overall  percent  agreement,  and  strength  of  this  agreement  relative  to  an  
expected  value  (measured  by  a  Kappa  statistic,  K),  was  determined  for  self-­‐‑collected  and  
clinician-­‐‑collected  samples.    The  Kappa  statistic  was  evaluated  on  a  scale  from  –  1  to  1,  
where  negative  values  indicate  agreement  less  than  chance  (i.e.  potential  systematic  
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disagreement  between  the  inter-­‐‑rater  categories),  “0”  is  exactly  what  one  would  expect  
by  chance,  and  positive  values  signify  agreement  better  than  chance  48.    A  confidence  
interval  was  determined  for  the  Kappa  statistic  using  an  analytical  method  for  
dichotomous  variables  that  is  standard  in  STATA  12.0  99.    Strength  of  HR  HPV  test  
agreement  was  similarly  calculated  for  age  percentage  quartiles  (with  ranges  of  23  –  34,  
35  –  41,  42  –  48,  and  49  –  68  years)  and  biopsy  result  categories  (HPV  cytopathic  effect,  
CIN  I,  CIN  II,  CIN  III,  squamous  cell  carcinoma/  cancer).    For  patients  who  were  
randomly  biopsied  in  four  cervical  quadrants,  the  highest  level  of  disease  found  in  any  
of  the  quadrants  was  reported  and  used  for  analysis.    Relationships  between  nominal  
variables  were  calculated  using  chi-­‐‑square  or  Fisher’s  Exact  tests.    The  latter  was  
conducted  for  concomitant  HR  HPV  test  results  vs.  biopsy  results  because  of  the  small  
sample  size.    McNemar’s  test  was  used  to  compare  paired  sets  of  data.  







7.1 Study Population Characteristics 
The  median  age  of  women  enrolled  in  the  study  was  46  years.    The  mean  age  was  
41  years,  and  the  median  range  of  participants  (25-­‐‑75%  quartiles)  fell  between  34  and  48  
years.    Five  women’s  ages  were  outside  of  the  inclusion  criteria;  there  were  three  23  
year-­‐‑olds,  one  24  year-­‐‑old,  and  one  68  year-­‐‑old.    80.6%  of  participants  were  married  or  
living  with  a  partner.    The  majority  of  women  (62.37%)  had  only  one  or  two  sexual  
partners  in  their  lifetimes,  but  half  (50.76%)  of  the  women’s  partners  had  children  with  
other  women.    On  average,  women  had  two  or  three  living,  biological  children  (mean  =  
2.43,  SD  +/-­‐‑  1.87),  and  made  their  sexual  debuts  at  19.78  years  of  age  (SD  +/-­‐‑  4.59).    27.3%  
of  women  had  experienced  at  least  one  miscarriage  during  pregnancy,  while  41.3%  had  
electively  terminated  at  least  one  pregnancy.      
 
7.2. Test Positivity and Disease Prevalence Rates 
High-­‐‑risk  HPV  DNA  was  detected  in  21.41%  (393/  1836)  of  self-­‐‑collected,  vaginal  
samples  and  18.57%  (341/  1836)  of  health  worker-­‐‑collected,  cervical  samples.      24.29%  
(446/  1836)  of  women  had  at  least  one  HR  HPV  positive  test  result  and  were  referred  for  
follow-­‐‑up  diagnostic  testing.    Self-­‐‑screening  identified  88.10%  of  all  women  infected  
with  HR  HPV  in  their  reproductive  tracts,  compared  to  clinician  screening,  which  
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identified  76.40%.    Assuming  100%  sensitivity  of  HR  HPV  detection  for  clinician-­‐‑
screening,  self-­‐‑screening  missed  disease  in  15.54%  of  cervical  positive  cases;  in  other  
words,  vaginal  samples  identified  84.46%  (288/  341)  of  positive  cases  that  were  identified  
by  cervical  samples.  
  
Table  1.  Two-­‐‑by-­‐‑Two  Table  of  Concomitant  HR  HPV  Results  with  Percent  
Frequencies  
   Cervical  –   Cervical  +   Total  










Total   1495   341   1836  
  
  
Vaginal  samples  garnered  higher  rates  of  positivity  than  cervical  samples  among  
all  age  groups.    Both  vaginal  and  cervical  HR  HPV  prevalence  decreased  with  age,  
although  the  oldest  quartile  (49  –  68  years)  had  slightly  higher  prevalence  than  42  to  48  
year-­‐‑olds.    Prevalence  rates  differed  with  statistical  significance  (p  <  0.001)  by  age  
quartile,  according  to  chi-­‐‑square  tests  within  all  three  diagnostic  categories  of  interest:  
vaginal  positive,  cervical  positive,  and  vaginal  or  cervical  positive.    McNemar’s  chi-­‐‑
square  test  indicated  that  prevalence  rates  garnered  by  self-­‐‑  and  clinician-­‐‑screenings  
were  significantly  different  for  the  youngest  and  oldest  age  quartiles,  but  were  
statistically  comparable  in  the  other  categories.  
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Table  2.  HR  HPV  Prevalence  by  Age  Quartile  













(Vaginal  +  or  
Cervical  +)  
0  –  25%  
(n  =  490)  
  




27.55%   *9.62  
p  <  0.01  
35.51%  
26  –  50%  
(n  =  435)  
  
35  –  41  
  
22.53%   21.15%   0.95  
p  =  0.33  
26.21%  
51  –  75%  
(n  =  458)  
  
42  –  48  
  
13.76%   11.57%   3.33  




(n  =  453)  
49  –  68  
  
16.34%   13.47%   *4.83  





p  <  0.001  
*50.68  
p  <  0.001  
N/A   *59.30  
p  <  0.001  
  
  
At  the  time  of  publishing,  80.90%  (360/  445)  of  HR  HPV  positive  women  had  
completed  colposcopy  and  biopsy.    Histopathology  results  were  available  for  33.89%  
(122/  360)  of  completed  biopsies.    Five  HPV  negative  women  were  inadvertently  
biopsied  due  to  staff  oversight,  and  their  histopathology  results  are  pending.    Of  the  
biopsies  with  results  available  to  date,  8.20%  (10/122)  presented  with  benign  mucosa,  
39.34%  (48/122)  with  HPV  cytopathic  effect,  43.44%  (53/122)  with  CIN  I,  4.10%  (5/  122)  
with  CIN  II,  3.28%  (4/  122)  with  CIN  III,  and  1.64%  (2/  122)  with  cancer.    
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7.3 Test Agreement  
Overall,  there  was  a  91.39%  (1677/  1836)  agreement  between  the  concomitant  HR  
HPV  tests  (K=  0.73  [95%  CI:  0.69  –  0.77],  SE=  0.02,  p  <  0.001).    This  agreement  is  much  
greater  than  the  statistically  expected  value  of  68.03%,  as  evinced  by  the  proximity  of  the  
Kappa  statistic  to  “1,”  which  suggests  perfect  agreement.    Kappa  statistics  within  the  
range  of  0.61  –  0.81  are  considered  to  denote  “good”  strength  of  agreement79.      
When  stratifying  HR  HPV  test  results  by  age  quartile,  chi-­‐‑square  testing  
demonstrated  that  age  had  a  statistically  significant  (p  <  0.05)  impact  on  concomitant  
results’  test  agreement,  and  reiterated  the  connections  between  age  and  vaginal  results,  
and  age  and  cervical  results.    There  was  a  general  trend  towards  greater  test  
concordance  with  increasing  age,  although  42  to  48  year-­‐‑olds  had  higher  concordance  
(93.45%)  than  the  oldest  age  group,  49  to  68  year-­‐‑olds  (92.46%).    All  corresponding  
Kappa  statistics  (range:  0.69  to  0.74)  indicated  statistically  significant,  substantial  
strengths  of  agreement  (Table  3).    It  is  unlikely  that  the  observed  agreement  between  test  






Table  3.  Concomitant  HR  HPV  Test  Agreement  by  Age  Quartile  
Quartile   Age  
Range  
(Years)  









0  –  25%  
(n  =  490)  
23  –  34  
  
316   16   39   119   88.78%  
  
0.73  
[0.67  –  0.80]  
p  <  0.001  
26  –  50%  
(n  =  435)  
35  –  41  
  
321   16   22   76   91.26%  
  
0.74  
[0.67  –  0.82]  
p  <  0.001  
51  –  75%  
(n  =  458)  
  42  –  48  
  
385   10   20   43   93.45%  
  
0.70  
[0.61  –  0.80]  
p  <  0.001  
76  –  100%  
(n  =  453)  
  49  –  68  
  
368   11   24   50   92.27%  
  
0.69  




            *7.19  




7.4 Detection of CIN 
Vaginal  brush  samples  identified  90.63%  of  women  known  to  have  ≥  CIN  I  
(Table  4),  and  90.91%  known  to  have  ≥  CIN  II  (Table  6).    Vaginal  screening  alone  would  
have  missed  six  cases  of  CIN  I  and  one  case  of  CIN  II.    Cervical  brush  samples  
performed  slightly  better  by  detecting  95.31%  of  patients  with  ≥  CIN  I  (Table  5),  and  
100%  with  ≥  CIN  II  (Table  7).    Cervical  screening  alone  would  have  missed  three  cases  of  
CIN  I.        Both  tests  detected  100%  of  CIN  III  and  cancer  cases.    Detection  rates  of  ≥  CIN  I  
were  comparable  (p  =  0.74)  according  to  a  Fisher’s  Exact  Test,  which  was  unable  to  be  
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performed  on  a  two-­‐‑by-­‐‑two  contingency  table  of  ≥  CIN  II  detection  rates  due  to  an  
insufficient  number  of  observations  in  each  of  the  cells.  
Similarly,  for  the  individual  histopathological  categories,  p  values  could  only  be  
generated  for  the  HR  HPV  test  results  of  patients  with  HPV  Cytopathic  Effect  and  CIN  I.  
The  tests  of  association  conveyed  that  there  were  no  statistical  differences  in  the  
detection  rates  of  vaginal  and  cervical  tests  within  the  two  histopathological  categories  














Table  4.  Two-­‐‑by-­‐‑Two  Table  of  Self-­‐‑Collected,  Vaginal  Samples'ʹ  HR  HPV  
Results  vs.  ≥  CIN  I  Diagnosis  
   <  CIN  I   ≥  CIN  I   Total  
Vaginal  –      5      6   11  
Vaginal  +   53   58   111  
Total   58   64   122  
  
  
Table  5.  Two-­‐‑by-­‐‑Two  Table  of  Clinician-­‐‑Collected,  Cervical  Samples'ʹ  HR  HPV  
Results  vs.  ≥  CIN  I  Diagnosis  
   <  CIN  I   ≥  CIN  I   Total  
Cervical  –   16   3   19  
Cervical  +   42   61   103  
Total   58   64   122  
  
  
Table  6.  Two-­‐‑by-­‐‑Two  Table  of  Self-­‐‑Collected,  Vaginal  Samples'ʹ  HR  HPV  
Results  vs.  ≥  CIN  II  Diagnosis  
   <  CIN  II   ≥  CIN  II   Total  
Vaginal  –   10   1   11  
Vaginal  +   101   10   111  
Total   111   11   122  
  
  
Table  7.  Two-­‐‑by-­‐‑Two  Table  of  Clinician-­‐‑Collected,  Cervical  Samples'ʹ  HR  HPV  
Results  vs.  ≥  CIN  II  DIagnosis  
   <  CIN  II   ≥  CIN  II   Total  
Cervical  –   19   0   19  
Cervical  +   92   11   103  
Total   111   11   122  
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(n  =  10)  




(n  =  48)  
-­‐‑-­‐‑   5   8   35   89.58%  
  
83.33%   0.38  
CIN  I  
(n  =  53)  
-­‐‑-­‐‑   5   3   45   90.57%  
  
94.34%   0.74  
CIN  II    
(n  =  5)  
-­‐‑-­‐‑   1   -­‐‑-­‐‑   4   80.00%  
  
100.00%   -­‐‑-­‐‑  
CIN  III    
(n  =  4)  
-­‐‑-­‐‑   -­‐‑-­‐‑   -­‐‑-­‐‑   4   100.00%  
  
100.00%   -­‐‑-­‐‑  
Cancer    
(n  =  2)  
-­‐‑-­‐‑   -­‐‑-­‐‑   -­‐‑-­‐‑   2   100.00%  
  
100.00%   -­‐‑-­‐‑  
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8. Limitations 
Several  issues  related  to  biopsy  collection  and  diagnosis  limited  the  analysis  and  
interpretation  of  the  histopathology  dataset.    At  the  time  of  publication,  the  dataset  was  
incomplete:  360/  445  HR  HPV  positive  women  had  been  biopsied,  and  122  had  results.    
Without  a  robust  sample  size  that  included  more  than  a  few  women  with  ≥  CIN  II,  it  was  
difficult  to  assess  with  certainty  the  vaginal  and  cervical  screens’  abilities  to  identify  
women  with  high-­‐‑grade  disease.      
This  assessment  might  also  have  been  hampered  by  the  time  lapse  between  
screening  for  HR  HPV  and  performing  colposcopy  and  biopsy.    For  the  360  HR  HPV  
positive  women  who  have  been  biopsied  to  date,  the  average  amount  of  time  between  
their  HR  HPV  test  and  biopsy  was  61  days.    25%  had  more  than  a  6-­‐‑month  time  gap  
between  initial  and  follow-­‐‑up  visits.    During  the  time  between  screening  and  
undergoing  biopsies,  it  is  possible  that  some  women’s  infections  cleared,  while  others’  
advanced.    If  an  infection  digressed  or  progressed  enough  to  alter  the  viral  load  of  HR  
HPV  DNA  in  the  reproductive  tract  (which  corresponds  to  hc2  signal  strength  that  is  
used  to  determine  positivity),  the  initial  test  results  could  be  an  inaccurate  reflection  of  
the  woman’s  HR  HPV  status  at  the  time  of  biopsy.        
However,  some  scientists  might  contest  this  idea.    Schiffman  and  colleagues  
(2011)  suggest  that  waiting  an  unspecified  amount  of  time  between  primary  screening  
and  colposcopy  could  actually  improve  accuracy  over  same-­‐‑day  biopsies.    They  contend  
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that  CIN  III  lesions  are  initially  difficult  to  spot  because  of  their  small  size,  leading  
clinicians  to  inadvertently  miss  high-­‐‑grade  disease100.    Indeed,  colposcopies  are  a  highly  
subjective  screening  method.    Current  guidelines  direct  colposcopists  to  biopsy  the  
“most  worrisome”  visible  lesion,  but  intercolposcopist  agreement  upon  where  the  
biopsy  ought  to  be  taken  is  mediocre.    In  this  study,  two  clinicians,  trained  in  different  
countries,  performed  the  procedure101-­‐‑102.    Studies  show  that  single  colposcopic  
examinations  miss  approximately  one  third  of  CIN  II  and  III  lesions103,104.    Increasing  the  
number  of  biopsies  taken  does  improve  sensitivity,  however,  regardless  of  the  
experience  of  the  colposcopist105,106,107.    Therefore,  it  is  possible  that  subjects  who  
underwent  four-­‐‑quadrant  biopsies  received  more  sensitive  results  than  those  who  were  
biopsied  only  once  from  their  most  suspicious  lesion.    In  fact,  data  analysis  on  the  
incomplete  dataset  of  multiple,  random  biopsies  does  indicate  the  presence  of  high-­‐‑
grade  disease  in  samples  with  healthy  appearance.    
The  pathologists  who  were  not  blinded  to  the  HR  HPV  results  introduced  
additional  bias.    Knowing  the  vaginal  and  cervical  results  could  have  influenced  them  to  
downgrade  their  diagnoses  for  women  who  tested  negative  for  cervical  HR  HPV,  but  
positive  for  vaginal  HR  HPV.    Branding  true  positives  as  false  positives  could  have  
reduced  the  vaginal  test’s  sensitivity  for  clinically-­‐‑relevant  disease.    All  ten  diagnoses  of  
“benign  mucosa”  were  associated  with  samples  that  were  positive  for  vaginal  HPV,  
while  only  two  were  positive  for  cervical  HPV.    Global  research  has  demonstrated  that  
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the  pathological  interpretation  of  cervical  biopsies  is  sometimes  subjective,  documenting  
poor  inter-­‐‑observer  and  intra-­‐‑observer  reproducibility  of  diagnoses  of  CIN  II  and  III36.    
Lastly,  this  study’s  results  could  have  been  enhanced  by  the  inclusion  of  
sensitivity  and  specificity  calculations  for  both  cervical  and  vaginal  samples.    A  
screening  method’s  sensitivity  and  specificity  are  fundamental  to  its  selection  as  a  useful  
tool  for  cancer  prevention,  as  they  reveal  information  needed  to  estimate  testing  
intervals  and  choose  secondary  or  triage  tests.    Without  a  universally  applied  reference  
standard  in  this  study—only  HR  HPV  positive  women  were  assessed  by  colposcopy  and  
histology—this  information  was  incalculable.    The  absence  of  a  reference  standard  
diminished  the  understanding  of  the  concomitant  screening  tests’  power  of  disease  
detection,  and  though  unlikely,  might  have  denied  at-­‐‑risk  women  (who  received  false  









To  assess  the  generalizability  of  results,  and  to  place  this  discussion  in  the  
appropriate  context,  it  was  important  to  compare  this  study  population  to  the  broader  
Haitian  and  Caribbean/  Latin  American  populaces.    In  general,  the  makeup  of  this  
sample  from  Port-­‐‑au-­‐‑Prince  appears  to  closely  represent  the  overall  Haitian,  adult,  
female  population.  
The  World  Health  Organization  (WHO)  and  Institute  Catala  d’Oncologia  (2010)  
estimated  that  the  median  age  of  first  sexual  intercourse  among  Haitian  women  
currently  between  the  ages  of  25  and  49  years  is  18.1  years  old.    Within  the  same  age  
bracket,  members  of  this  study  population  had  a  median  age  of  sexual  debut  of  18,  and  a  
mean  of  19.5  years.    HIV  prevalence  in  this  population  (2.23%)  also  matched  the  latest  
WHO  countrywide  estimate  for  adults  between  the  ages  of  15  and  49  years  (2.20%).    As  
one  would  expect,  the  prevalence  rate  among  participants  (most  of  whom  had  only  one  
or  two  lifetime  sexual  partners)  was  considerably  lower  than  estimates  for  female  sex  
workers  in  Port-­‐‑au-­‐‑Prince  (5%)108.  
According  to  the  Haitian  Demographic  and  Health  Survey  (2000),  55%  of  men  
engaged  in  extramarital  sex  within  the  last  year.    While  respondents  were  not  asked  
specifically  about  their  partners’  faithfulness  (due  to  the  cultural  complexity  of  the  
issue),  they  were  asked  to  report  if  their  partners  had  children  with  other  women.    51%  
responded  affirmatively.    Although  a  direct  comparison  between  these  statistics  cannot  
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be  made,  the  numbers  are  related,  particularly  given  that  contraception  is  not  widely  
practiced  in  Haiti.    Only  3.3%  of  all  Haitian  women  use  oral  contraception,  and  24.8%  of  
married  women  use  some  form  of  modern  contraception108;  therefore,  it  is  likely  that  
many  extramarital  relationships  result  in  pregnancy.    
More  than  99%  of  study  participants  reported  affiliation  with  a  particular  
religion.    Most  identified  themselves  as  Protestant  (60.84%),  Catholic  (19.61%),  or  
Christian  (16.94%)—the  remaining  described  themselves  as  Mormons  or  Jehovah’s  
Witnesses.    While  the  term  “Christian”  can  refer  to  a  follower  of  any  Christian  
denomination,  in  Haiti,  Protestants  more  often  espouse  the  label  than  Catholics.    With  or  
without  considering  self-­‐‑identified  Christians  as  Protestants,  the  prevalence  of  
Protestantism  among  the  national  female  population  (53%)  is  significantly  lower  than  
among  study  participants,  while  Catholicism  (39%)  is  significantly  higher—in  fact,  
double—than  among  study  participants  109.    Given  that  women  were  actively  recruited  
from  local  Protestant  churches,  this  skewed  religious  distribution  is  unsurprising.    
However,  as  religious  affiliation  is  of  unknown  association  with  HPV  or  its  risk  factors  
in  this  study  or  the  broader  Haitian,  it  is  impossible  to  draw  conclusions  about  external  




Table  9.  Cervical  Cancer  Risk  Factors:  Study  Population  vs.  National  Population  
Cervical  Cancer  Risk  Factors   Study  Population  (2012)   Haitian  Population  (2010)  
HIV  Prevalence   2.23%   2.20%  
Age  of  Sexual  Debut   18  years   18.1  years  
Male  Partner  has  
Additional  Female  
Partner  
51%   55%  
  
  
9.1 HR HPV Self-Screening’s Diagnostic Performance 
9.1.1 Test Agreement 
The  results  generated  from  this  study  portend  a  promising  future  for  vaginal,  
self-­‐‑screening  in  Haiti.    By  all  measures,  the  prevention  method  scored  on  par  with  the  
highly  sensitive,  established  technique  of  cervical,  clinician-­‐‑performed  screening.    Two  
of  the  three  hypotheses  subtending  the  primary  research  objective  came  to  fruition,  
while  the  third  fell  short  by  less  than  five  tenths  of  a  percentage  point.    In  manifesting  
these  predictions,  self-­‐‑screening  in  Haiti  equaled  or  rivaled  its  diagnostic  performance  in  
other  settings.  
Displaying  91.39%  concordance  with  cervical  samples,  vaginal  samples  exceeded  
the  statistical  expectations  for  chance  agreement  alone  (68.03%)  with  a  strong  Kappa  
value  (0.73).    These  numbers  almost  identically  match  those  from  previous  studies  in  
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Brazil,  Germany,  China,  and  India56,64,87,110,  and  demonstrate  an  improvement  over  those  
recorded  by  researchers  in  Gugulanthu,  South  Africa  and  Munich,  Germany84,86.    The  
consistent,  diagnostic  performance  of  self-­‐‑sampling  against  clinician-­‐‑sampling  augments  
its  broad,  cross-­‐‑cultural  appeal  as  an  alternative  to  more  invasive  methods  of  screening.      
9.1.2 Detection of Cervical Positivity 
It  was  hypothesized  that  vaginal  samples  would  contain  HR  HPV  in  at  least  85%  
of  positive  cervical  cases,  and  the  reality  came  close  at  84.46%.    This  number  is  not  very  
informative  on  its  own,  however.    To  determine  the  significance  of  the  discrepancy,  one  
must  examine  the  histopathological  characteristics  of  the  women  who  tested  negative  for  
HR  HPV  in  the  vagina  but  positive  in  the  cervix.    53  women  fit  this  criteria,  and  of  those,  
11  have  biopsy  results:  five  were  diagnosed  with  HPV  cytopathic  effect,  five  with  CIN  I,  
and  one  with  CIN  II.    Because  low-­‐‑grade  disease  most  often  corresponds  to  transient  
infection,  it  is  generally  of  little  concern  to  clinicians.    However,  in  Haiti,  because  women  
are  rarely  screened,  CIN  I  lesions  are  sometimes  preemptively  treated  with  cryotherapy.    
In  order  to  catch  CIN  I  in  the  future,  pathologists  might  consider  adjusting  the  RLU/CO  
cut-­‐‑off  value  which,  at  1  pg/mL,  is  designed  to  identify  cases  of  ≥  CIN  III  with  near-­‐‑
perfect  sensitivity.    If  the  RLU/CO  cut-­‐‑off  value  were  adjusted  to  0.5  pg/mL  for  vaginal  
samples,  self-­‐‑screening  would  have  identified  one  more  case  of  disease;  if  it  had  been  
adjusted  to  0.4  or  0.3  pg/mL,  three  to  five  more  cases  of  disease  would  have  been  
identified,  respectively.    With  a  dataset  of  only  11  biopsy  results  in  this  category,  it  is  
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difficult  to  interpret  the  benefit  of  a  lower  cut-­‐‑off  value  at  this  time.    Based  on  other  
study’s  findings,  it  would  be  prudent  to  re-­‐‑examine  this  issue  once  the  dataset  is  
complete.      
9.1.3 Detection of CIN 
Although  demonstrating  comparability  to  an  inveterate  test  is  important  to  
proving  functionality,  affirming  an  ability  to  detect  pre-­‐‑cancerous  and  cancerous  disease  
is  salient  to  proving  efficacy.    Of  biopsy-­‐‑confirmed  cases  of  ≥  CIN  I  and  ≥  CIN  II,  vaginal  
samples  identified  HR  HPV  in  90.63%  and  90.91%  of  them,  respectively.    A  Fisher’s  
Exact  Test  revealed  that  cervical  samples’  detection  rate  was  not  significantly  higher  for  
≥  CIN  I  (p=0.74);  though  a  test  of  association  could  not  be  conducted  on  ≥  CIN  II  samples  
due  to  inadequate  sample  size,  cervical  samples  led  vaginal  samples  by  9%.    However,  it  
is  likely  that  the  gap  will  narrow  with  more  cases  of  high-­‐‑grade  disease  based  on  the  
currently  available  data:  self-­‐‑screening  identified  four  of  the  five  women  with  CIN  II,  
and  100%  of  those  with  CIN  III  and  cancer.    While  the  detection  rates  from  this  study  
cannot  be  equated  to  the  sensitivities  reported  in  others  (due  to  the  absence  of  a  
universally-­‐‑applied  reference  standard),  they  do  suggest  powerful  diagnostic  capability.  
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9.2 Age-Related Statistics 
9.2.1 Prevalence Rates 
To  imbue  test  results  with  greater  meaning,  age-­‐‑related  statistics  were  generated,  
as  the  links  between  age,  HPV  prevalence,  and  hc2  test  performance  are  well-­‐‑
documented.    As  hypothesized,  HR  HPV  prevalence  rates  (overall,  vaginal,  and  cervical)  
varied  with  statistical  significance  by  age  quartile,  with  the  youngest  (23-­‐‑34  years)  
bearing  the  greatest  burden  and  the  middle-­‐‑aged  (42-­‐‑48  years)  bearing  the  least.    As  has  
been  observed  in  other  countries  in  the  Latin  American  region  (Brazil,  Costa  Rica,  Chile,  
Colombia,  and  Mexico)  and  in  Holland,  a  second  peak  in  prevalence  occurred  in  the  
oldest  age  cohort  (49-­‐‑68  years)11,88,111.      
Three  explanations  may  be  offered  for  this  dilatory  spike  in  prevalence,  though  
all  suggest  hc2  test  mal-­‐‑performance.    Bacterial  infections  and  LR  HPV,  the  latter  
especially  known  to  affect  post-­‐‑menopausal  women  more  than  other  age  groups,  
sometimes  cross-­‐‑react  with  the  hc2  probe  to  cause  false  positive  results88,112.    
Additionally,  douche  and  vaginal  jellies  are  believed  to  impact  results14.    It  has  been  
reported  in  studies  from  Little  Haiti,  Miami,  that  Haitian  women  douche  several  times  a  
day  as  part  of  ingrained  tradition,  particularly  out  of  concern  for  vaginal  muscle  tone43,45.    
It  is  possible  that  older  women  engage  in  this  practice  more  often  than  younger  women,  
thus  rendering  their  HPV  tests  more  vulnerable  to  chemical  interference.    Furthermore,  
because  hygiene  conditions  are  poor  in  Haiti,  and  douching  products  used  are  both  
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natural  and  synthetic,  it  is  possible  that  douching  may  be  responsible  for  the  high  
prevalence  of  inflammatory  reproductive  tract  infections  –  again,  a  possible  source  of  
hc2  cross-­‐‑reactivity113,114.    Although  it  is  impossible  to  discern  the  source  of  the  second  
prevalence  peak  from  this  study’s  data  alone,  there  is  a  compelling  case  to  investigate  
HR  HPV  and  LR  HPV  genotypes  in  the  Haitian  population.    Future  community-­‐‑based  
trials  would  also  benefit  from  incorporating  an  educational  component  that  cautions  
women  of  the  dangers  of  frequent  douching,  or  at  least  the  need  to  desist  for  several  
days  before  submitting  a  vaginal  sample  for  HR  HPV  testing.  
9.2.2 Test Agreement 
Interestingly,  prevalence  rates  not  only  vary  by  age,  but  by  testing  location.    
While  vaginal  and  cervical  samples’  positivity  were  comparable  among  the  median  50%  
of  subjects,  they  differed  with  statistical  significance  among  the  youngest  and  oldest  
quartiles.    There  are  a  couple  of  possible  explanations  for  the  difference  in  vaginal  and  
cervical  specimens  of  23  –  34  year-­‐‑olds:  new  sex  partners  and  incident  infections.    One  
study  showed  that  HR-­‐‑HPV  is  associated  with  vaginal  samples  in  the  first  four  months  
after  intercourse  with  a  new  partner,  but  is  only  associated  with  cervical  samples  at  least  
five  months  after  sex  with  a  new  partner9.    Because  young  women  may  be  more  likely  to  
have  had  sex  recently,  and  with  a  new  partner,  than  older  women,  it  makes  sense  that  
they  would  have  higher  vaginal  positivity  than  cervical  positivity.    Marriage  rates  
among  the  youngest  cohort  compared  to  the  others  corroborates  this  assumption  that  
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older  women  are  more  likely  to  be  monogamous.    Young  women  are  also  more  likely  
than  older  women  to  experience  incident  infections  that  clear  before  migrating  from  the  
vulvovaginal  area  into  the  cervical  tissue115.  
Possibly  impacting  the  results  of  both  the  youngest  and  oldest  women  in  the  
study  is  the  globally-­‐‑documented  increased  prevalence  of  LR  HPV  in  these  age  groups.    
LR  HPV,  which  can  cross-­‐‑react  with  hc2  to  produce  false  positive  results,  has  been  
found  to  occur  more  often  in  the  vagina  than  in  the  cervix86,88.    In  fact,  among  450  women  
at  community  health  clinics  in  South  Africa,  LR  HPV  was  twice  as  common  in  self-­‐‑
collected  samples  than  clinician-­‐‑collected  samples86.    These  statistics  reiterate  the  need  











Cervical  cancer  should  be  a  vestige  of  a  bygone  era  in  which  prevention  
strategies  like  screening,  vaccinations,  and  early  treatment  of  pre-­‐‑cancerous  lesions  were  
yet  to  be  conceived.    Instead,  the  disease  persists  as  one  of  the  most  common  and  deadly  
to  women  worldwide,  though  disproportionately  to  those  in  low-­‐‑income  countries.    
Haiti,  a  nation  with  scant  health  data  and  a  negligible  national  budget,  lacks  a  cervical  
cancer  screening  program  despite  possessing  the  highest  reported  cervical  cancer  
incidence  and  mortality  rates  in  the  region.    With  numerous  financial,  geographic,  and  
cultural  barriers  to  the  health  system,  screening  coverage  rates  have  remained  abysmally  
low.    Based  on  acceptability  studies  in  Little  Haiti,  preliminary  research  by  Partners  in  
Health,  and  the  data  presented  in  this  paper,  it  appears  that  self-­‐‑screening  for  HPV  is  a  
suitable  approach  to  curbing  the  incidence  and  mortality  of  cervical  cancer  in  Haiti.  
In  accordance  with  reports  from  other  low-­‐‑resource  settings,  vaginal  self-­‐‑
screening  in  Port-­‐‑au-­‐‑Prince  demonstrated  strong  diagnostic  ability.    The  method  proved  
highly  concordant  with  cervical,  clinician-­‐‑performed  screening,  and  demonstrated  an  
ability  to  detect  the  preponderance  of  known  cases  of  high-­‐‑grade  disease.    Interestingly,  
data  indicate  that  while  hc2  test  performance  is  strong  for  women  of  all  ages,  vaginal  
and  cervical  results  can  disagree  by  a  significant  margin  in  women  under  34  and  above  
49.    In  both  cohorts,  vaginal  positivity  was  greater  than  cervical  positivity.    Previous  
research  supports  several  explanations  involving  recent  and  transient  infections  and  hc2  
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cross-­‐‑reactivity  with  bacteria,  vaginal  jellies  or  douche  products,  and  LR  HPV.    With  
age-­‐‑related  prevalence  data,  hc2  cut-­‐‑off  values  can  be  adjusted  to  accommodate  for  
possible  interference.    In  Haiti,  the  optimal  test  would  detect  all  cases  of  ≥  CIN  II  and  
most  cases  of  CIN  I.    Catching  and  treating  disease  early  is  an  advantage  in  a  setting  
where  women  rarely  interact  with  the  health  system  and  have  limited  access  to  surgery  
or  radiotherapy  for  advanced  cancer.      
Further  research  should  focus  on  genotyping  both  HR  HPV  and  LR  HPV  in  the  
vagina  and  cervix.    This  information  would  help  clarify  the  potential  for  hc2  cross-­‐‑
reactivity  and  the  risk  for  progression  of  infection.    ROC  curves  can  optimize  hc2  test  
algorithms  for  different  populations,  taking  into  account  the  health  and  economic  results  
that  come  with  favoring  either  sensitivity  or  specificity.    In  establishing  age-­‐‑specific  hc2  
detection  levels,  it  could  also  be  useful  to  explore  the  relationships  between  HPV  viral  
load  and  CIN,  and  viral  load  and  testing  location  (lower  vagina,  upper  vagina,  and  
cervix).    Interesting  hypotheses  and  data  have  been  generated  on  the  topics9,86,87,  but  the  
body  of  research  is  not  yet  robust  enough  to  be  considered  conclusive  or  clinically  
useful.    Armed  with  more  detailed  knowledge  of  HPV  test  results,  colposcopists  and  
pathologists  in  Haiti  could  be  supported  in  rendering  diagnoses  and  consequently  
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